Skip to main content
Pipeline Watchlist

Company Pipelines

Companies

Novartis AG

novartis.com
62assets
  • LutatheraAAA601 / Lutathera / SSTR / Radioligand therapy / Oncology: Solid Tumors
    Gastroenteropancreatic neuroendocrine tumorsPhase 3Supplementary; filing 2028GEPNET, pediatricsPhase 2
  • 177Lu-NeoBAAA603 / GRPR / Radioligand therapy / Oncology: Solid Tumors
    Breast cancerPhase 1Multiple solid tumorsPhase 2Lead; filing >= 2029
  • AAA614FAP / Radioligand therapy / Oncology: Solid Tumors
    Solid tumorsPhase 2Lead
  • PluvictoAAA617 / Pluvicto / PSMA / Radioligand therapy / Oncology: Solid Tumors
    Oligometastatic prostate cancerPhase 3Supplementary; filing >= 2029Metastatic hormone sensitive prostate cancer (mHSPC)RegistrationSupplementary
  • 225Ac-PSMA-617AAA817 / PSMA / Radioligand therapy / Oncology: Solid Tumors
    Metastatic castration-resistant prostate cancer (mCRPC)Phase 3Supplementary; filing >= 2029post Lu Metastatic castration-resistant prostate cancer (mCRPC)Phase 3Lead; filing 2028
  • ScemblixABL001 / Scemblix / BCR-ABL / Inhibitor / Oncology: Hematology
    Chronic myeloid leukemia, pediatricsPhase 2Supplementary; filing 2027
  • CosentyxAIN457 / Cosentyx / IL17A / Inhibitor / Immunology
    Polymyalgia rheumaticaRegistrationSupplementary; filing 2026
  • AimovigAMG334 / Aimovig / CGRPR / Antagonist / In-market Brands and Global Health
    Migraine, pediatricsPhase 3Supplementary; filing 2028
  • AMO959DNA PK / Inhibitor / Oncology: Solid Tumors
    Prostate cancerPhase 1Lead
  • MayzentBAF312 / Mayzent / S1P1,5 receptor modulator / Neuroscience
    Multiple sclerosis, pediatricsPhase 3Supplementary; filing 2027
  • VijoyceBYL719 / Vijoyce / PI3K-alpha / Inhibitor / Oncology: Solid Tumors
    Lymphatic malformationsPhase 3Supplementary; filing >= 2029
  • farabursenCYX082 / MIR17 / Inhibitor / Cardiovascular, Renal and Metabolic
    Autosomal dominant polycystic kidney diseasePhase 1Lead
  • pelabresibDAK539 / BET / Inhibitor / Oncology: Hematology
    MyelofibrosisPhase 3Lead; filing 2026
  • DFT383CTNS gene delivery / Neuroscience
    CystinosisPhase 1Lead
  • DII235siRNA targeting Lp(a) MRNA / Cardiovascular, Renal and Metabolic
    CVRR-Lp(a)Phase 2Lead; filing >= 2029
  • del-braxDWH213 / siRNA DUX4 knockdown / Neuroscience
    Facioscapulohumeral muscular dystrophyPhase 3Lead; filing 2028
  • tulmimetostatDZR123 / EZH1, EZH2 / Inhibitor / Oncology: Solid Tumors
    Metastatic prostate cancerPhase 1Solid tumors & lymphomasPhase 2Lead
  • ECI830CDK2 / Inhibitor / Oncology: Solid Tumors
    Breast cancerPhase 1Lead
  • EDI048CpPI(4)K / Inhibitor / In-market Brands and Global Health
    CryptosporidiosisPhase 2Lead
  • EDK060Lead Indication / Neuroscience
    Charcot-Marie-Tooth diseasePhase 1
  • ESP359DLL3 / Radioligand therapy / Oncology: Solid Tumors
    Solid tumorsPhase 1Lead
  • del-desiranEWF980 / siRNA DMPK knockdown / Neuroscience
    Myotonic dystrophy type 1Phase 3Lead; filing 2027
  • EYU688NS4B / Inhibitor / In-market Brands and Global Health
    Dengue feverPhase 2Lead
  • zigakibartFUB523 / Anti-APRIL / Cardiovascular, Renal and Metabolic
    IgA nephropathyPhase 3Lead; filing 2027
  • 177Lu-NNS309FXX489 / FAP / Radioligand therapy / Oncology: Solid Tumors
    Solid tumorsPhase 1Lead
  • GCJ904Lead Indication / Oncology: Solid Tumors
    Solid tumorsPhase 1
  • GHZ339Lead Indication / Immunology
    Atopic dermatitisPhase 2filing >= 2029
  • GIA632IL-15 mAb / Immunology
    Atopic dermatitisPhase 2Lead; filing >= 2029VitiligoPhase 2Supplementary; filing >= 2029
  • GXV813M4 / Agonist / Neuroscience
    SchizophreniaPhase 2Lead
  • HJB647Lead Indication / Cardiovascular, Renal and Metabolic
    Heart failurePhase 1
  • votoplamHTT227 / Huntingtin modulator / Neuroscience
    Huntington’s diseasePhase 3Lead; filing >= 2029
  • INE963Plasmodium falciparum / Inhibitor / In-market Brands and Global Health
    MalariaPhase 2Lead
  • IPX643Lead Indication / Immunology
    Inflammation-driven diseasesPhase 1
  • ITU512HbF inducing agent / In-market Brands and Global Health
    Sickle cell diseasePhase 1Lead
  • luxdegalutamideJSB462 / Androgen receptor protein degrader / Oncology: Solid Tumors
    Metastatic hormonal sensitive prostate cancerPhase 2Metastatic castration resistant prostate cancerPhase 2Lead; filing >= 2029
  • cipargaminKAE609 / PfATP4 / Inhibitor / In-market Brands and Global Health
    Malaria, uncomplicatedPhase 2Supplementary; filing >= 2029Malaria severePhase 2Lead; filing >= 2029
  • LeqvioKJX839 / Leqvio / siRNA (regulation of LDL-C) / Cardiovascular, Renal and Metabolic
    CVRR (primary prevention)Phase 3Supplementary; filing >= 2029CVRR (secondary prevention)Phase 3Supplementary; filing 2027
  • Ganaplacide + lumefantrineKLU156 / Non-artemisinin plasmodium falciparum / Inhibitor / In-market Brands and Global Health
    Malaria, uncomplicatedPhase 3Lead; filing 2026
  • del-zotaKPE179 / PMO mediated exon 44 skipping / Neuroscience
    Duchenne muscular dystrophyPhase 2Lead; filing 2026
  • FabhaltaLNP023 / Fabhalta / CFB / Inhibitor / Neuroscience / Cardiovascular, Renal and Metabolic / Oncology: Hematology / Others
    Generalized myasthenia gravisPhase 3Supplementary; filing 2027C3 glomerulopathy, pediatricsPhase 3IgAN, pediatricsPhase 3
  • RhapsidoLOU064 / Rhapsido / BTK / Inhibitor / Immunology
    Chronic spontaneous urticaria, pediatricsPhase 3Hidradenitis suppurativaPhase 3Supplementary; filing 2027Chronic inducible urticaria (CINDU)Phase 3Supplementary; filing 2026
  • remibrutinibLOU064 / BTK / Inhibitor / Neuroscience
    Multiple sclerosis, secondary progressivePhase 3Supplementary; filing >= 2029Myasthenia gravisPhase 3Supplementary; filing 2028Multiple sclerosis, relapsing remittingPhase 3Supplementary; filing 2027
  • LTP001SMURF1 / Inhibitor / Cardiovascular, Renal and Metabolic
    Idiopathic pulmonary fibrosisPhase 2Pulmonary arterial hypertensionPhase 2Lead; filing >= 2029
  • LXE408Proteasome / Inhibitor / In-market Brands and Global Health
    ChagasPhase 2Visceral leishmaniosisPhase 2Lead; filing >= 2029
  • abelacimabMAA868 / FXI / Inhibitor / Cardiovascular, Renal and Metabolic
    Atrial fibrillationPhase 3Lead; filing 2028
  • MAS825IL18 Inhibitor, IL1B / Immunology
    Still’s diseasePhase 2Lead
  • NIO752Tau antisense oligonucleotide / Neuroscience
    Alzheimer’s diseasePhase 1Progressive supranuclear palsyPhase 1Lead
  • OJR520Lead Indication / Cardiovascular, Renal and Metabolic
    CKDPhase 1
  • KesimptaOMB157 / Kesimpta / CD20 / Antagonist / Neuroscience
    Multiple sclerosis, new dosing regimenPhase 3Supplementary; filing 2027Multiple sclerosis, pediatricsPhase 3Supplementary; filing 2026
  • PAC001Anti-IL-6 mAb / Cardiovascular, Renal and Metabolic / Others
    ASCVD pacibekitugPhase 2Lead; filing >= 2029Thyroid eye disease (TED) pacibekitugPhase 2
  • PIT565Anti-CD19, Anti-CD2, Anti-CD3 / Immunology
    Systemic lupus erythematosusPhase 1Rheumatoid arthritisPhase 1
  • RydaptPKC412 / Rydapt / Multi-targeted kinase / Inhibitor / In-market Brands and Global Health
    Acute myeloid leukemia, pediatricsPhase 2Supplementary; filing 2027
  • PKN605HDAC6 / Inhibitor / Cardiovascular, Renal and Metabolic
    Atrial FibrillationPhase 2Lead
  • QCZ484Lead Indication / Cardiovascular, Renal and Metabolic
    HypertensionPhase 2filing >= 2029
  • AtecturaQMF149 / Atectura / LABA + ICS / In-market Brands and Global Health
    Asthma, pediatricsPhase 3Supplementary; filing >= 2029
  • AdakveoSEG101 / Adakveo / P-selectin / Inhibitor / In-market Brands and Global Health
    Sickle cell disease, pediatricsPhase 3Supplementary; filing >= 2029
  • TIN816ATP modulator / Cardiovascular, Renal and Metabolic
    Acute kidney injuryPhase 2Lead
  • pelacarsenTQJ230 / ASO targeting Lp(a) / Cardiovascular, Renal and Metabolic
    CVRR (secondary prevention) in patients with elevated Lp(a)Phase 3Lead; filing 2026
  • ianalumabVAY736 / BAFF-R inhibitor, ADCC-mediated B-cell depletor / Immunology / Oncology: Hematology
    Lupus NephritisPhase 3Supplementary; filing 2028Systemic lupus erythematosus (SLE)Phase 3Supplementary; filing 2028Systemic sclerosisPhase 2Supplementary; filing 2028
  • VHB937TREM2 stabilizer and activator / Neuroscience
    Amyotrophic lateral sclerosisPhase 2Lead; filing >= 2029Alzheimer's diseasePhase 2Supplementary; filing >= 2029
  • YMI024Lead Indication / Cardiovascular, Renal and Metabolic
    CVRRPhase 1
  • rapcabtagene autoleucelYTB323 / CD19 CAR-T / Immunology / Neuroscience / Oncology: Hematology
    Rheumatoid arthritis and severe, refractory Sjögren’s diseasePhase 1Systemic sclerosisPhase 2Supplementary; filing >= 2029MyositisPhase 2Supplementary; filing >= 2029

AbbVie

abbvie.com
37assets
  • ABBV-8736ABBV-8736 / TREM1 / Biologic / Immunology
    Crohn's DiseasePhase 2
  • TavapadonD1/D5 partial agonist / Small molecule / Neuroscience
    Parkinson's DiseaseSubmitted
  • ABBV-525ABBV-525 / MALT1 / Small molecule / Oncology
    Hematologic TumorsPhase 1
  • Telisotuzumab vedotinABBV-399 / EMRELIS / c-Met / Antibody-drug conjugate / Oncology
    Non-Small Cell Lung CancerApprovedUS
  • EpcoritamabGen3013 / EPKINLY/TEPKINLY / CD3, CD20 / Bispecific antibody / Oncology
    Relapsed/Refractory DLBCLApprovedUSEURelapsed/Refractory Follicular LymphomaApprovedRelapsed/Refractory CLLPhase 2
  • ABBV-466 (Skyrizi + ABBV-382)ABBV-466 / SKYRIZI / IL-23 + anti-a4b7 mAb / Biologic combination / Immunology
    Crohn's DiseasePhase 2
  • BudigalimabABBV-181 / PD1 / Biologic / Oncology
    Solid and Hematologic TumorsPhase 2
  • ABBV-701ABBV-701 / TL1A / Biologic / Immunology
    Inflammatory Bowel DiseasePhase 1
  • ABBV-932ABBV-932 / DRD2/DRD3 modulator / Small molecule / Neuroscience
    Bipolar DepressionPhase 2Generalized Anxiety DisorderPhase 2
  • ABBV-9832 (Lutikizumab + Ravagalimab)ABBV-9832 / IL-1a/1b + CD40 antagonist / Biologic combination / Immunology
    Rheumatoid ArthritisPhase 2
  • ABBV-6628ABBV-6628 / C5 / Biologic / Eye Care
    Geographic AtrophyPhase 1
  • ABBV-619ABBV-619 / CD19 / Biologic/CAR-T / Immunology
    Autoimmune diseasesPhase 1
  • LivmoniplimabABBV-151 / GARP-TGF-beta1 / Biologic / Oncology
    Hepatocellular CarcinomaPhase 2Solid TumorsPhase 2Non-Small Cell Lung CancerPhase 2
  • Armour ThyroidArmour Thyroid / T3T4 / Biologic / Other Specialties
    HypothyroidismPhase 3
  • ABBV-319ABBV-319 / CD19 / Biologic ADC / Immunology
    Sjogren's diseasePhase 1Systemic Lupus ErythematosusPhase 1
  • ABBV-722ABBV-722 / LPAR1 / Small molecule / Immunology
    Idiopathic Pulmonary FibrosisPhase 1Systemic SclerosisPhase 1
  • ABBV-142ABBV-142 / LPAR1 / Biologic / Immunology
    Idiopathic Pulmonary FibrosisPhase 1
  • ABBV-324ABBV-324 / Biologic ADC / Oncology
    Solid TumorsPhase 1
  • ABBV-295ABBV-295 / Long-Acting Amylin Analog / Large molecule / Other Specialties
    ObesityPhase 1
  • SurzetoclaxABBV-453 / BCL-2 / Small molecule / Oncology
    Relapsed/Refractory Multiple MyelomaPhase 1
  • ABBV-2002ABBV-2002 / PAR-2 / Biologic / Neuroscience
    MigrainePhase 2
  • IcalcaprantABBV-1354 / KOR antagonist / Small molecule / Neuroscience
    Bipolar DepressionPhase 2Major Depressive DisorderPhase 2
  • ABBV-1042ABBV-1042 / M4 receptor / Small molecule / Neuroscience
    Bipolar ManiaPhase 1
  • Surabgene LomparvovecABBV-RGX-314 / VEGF / Gene therapy / Eye Care
    wet AMD (subretinal)Phase 3wet AMD (suprachoroidal)Phase 2Diabetic Retinopathy (suprachoroidal)Phase 2
  • UbrogepantUBRELVY / CGRP receptor / Small molecule / Neuroscience
    Menstrual MigrainePhase 3
  • ABBV-2001ABBV-2001 / BCMA, CD38, CD3 / Biologic trispecific T-cell engager / Oncology
    Relapsed/Refractory Multiple MyelomaPhase 1
  • Pivekimab SunirinePVEK / CD123 / Biologic ADC / Oncology
  • Mirvetuximab soravtansineELAHERE / FR-alpha / Biologic ADC / Oncology
    Platinum-Resistant Ovarian CancerApprovedPlatinum-Sensitive Ovarian CancerPhase 3
  • AtogepantQULIPTA / CGRP receptor / Small molecule / Neuroscience
    Acute MigraineSubmittedOUSMenstrual MigrainePhase 3OUS
  • EmraclidineM4 PAM / Small molecule / Neuroscience
    SchizophreniaPhase 2PsychosisPhase 1
  • UpadacitinibABT-494 / RINVOQ / JAK1 / Small molecule / Immunology
    Alopecia AreataSubmittedUSEUHidradenitis SuppurativaPhase 3Systemic Lupus ErythematosusPhase 3
  • ABBV-166 (Skyrizi + Lutikizumab)ABBV-166 / SKYRIZI / IL-23 + IL-1a/1b / Biologic combination / Immunology
    Psoriatic ArthritisPhase 2
  • ABBV-848ABBV-848 / IRAK4 / Small molecule / Immunology
    Rheumatoid ArthritisPhase 1
  • ABBV-706ABBV-706 / SEZ6 / Biologic ADC / Oncology
    First Line Small Cell Lung CancerPhase 2Relapsed/Refractory Small Cell Lung CancerPhase 3Neuroendocrine NeoplasmsPhase 1
  • ABBV-1480ABBV-1480 / PD-1, VEGF / Biologic bispecific antibody / Oncology
    Solid TumorsPhase 1
  • LutikizumabABT-981 / IL-1a/1b / Biologic / Immunology
    Hidradenitis SuppurativaPhase 3
  • GemibotulinumtoxinAGemibotA / SNAP-25 / Biologic / Neuroscience
    Ventral Hernia RepairPhase 2

AstraZeneca PLC

astrazeneca.com
32assets
  • camizestrant + CDK4/6ingSERD + CDK4/6i / small molecule combination / Oncology
    1L HR+ HER2- ESR1m advanced breast cancerPhase IIISubmitted
  • camizestrant + palbociclibngSERD + CDK4/6i / small molecule combination / Oncology
    1L HR+ HER2- advanced breast cancerPhase III
  • camizestrant +/- abemaciclibngSERD + CDK4/6i / small molecule combination / Oncology
    adjuvant HR+ HER2- early breast cancerPhase III
  • camizestrantngSERD / small molecule / Oncology
    adjuvant switch HR+ HER2- early breast cancerPhase III
  • AZD0120AZD0120 / CD19/BCMA CAR-T / cell therapy / Oncology/Rare Disease/Respiratory & Immunology
    relapsed/refractory multiple myelomaPhase IIINew to Phase IIIamyloid light-chain amyloidosisPhase Isystemic lupus erythematosusPhase I
  • puxitatug samrotecanB7-H4 TOP1i ADC / antibody-drug conjugate / Oncology
    2-3L B7-H4+ endometrial cancerPhase III
  • rilvegostomigPD-1/TIGIT bispecific mAb / bispecific antibody / Oncology
    HCC; biliary tract; NSCLC; gastric cancerPhase III
  • saruparibPARP1 inhibitor / small molecule / Oncology
    prostate cancer; breast cancerPhase III
  • sonesitatug vedotinCLDN18.2 MMAE ADC / antibody-drug conjugate / Oncology
    CLDN18.2+ gastric cancerPhase III
  • surovatamigAZD0486 / CD19/CD3 T-cell engager / bispecific antibody / Oncology/Respiratory & Immunology
    1L elderly DLBCL; follicular lymphomaPhase IIIB-cell driven autoimmune diseasePhase I
  • torvutatug samrotecanAZD5335 / anti-FRα TOP1i ADC / antibody-drug conjugate / Oncology
    ovarian cancerPhase III
  • volrustomigPD-1/CTLA-4 bispecific mAb / bispecific antibody / Oncology
    cervical cancer; HNSCC; NSCLC; mesotheliomaPhase IIIcolorectal cancer; NSCLC; other solid tumoursPhase II
  • balcinrenone/dapagliflozinMR antagonist/modulator + SGLT2 inhibitor / small molecule combination / Cardiovascular, Renal and Metabolism
    heart failure with CKDPhase IIICKDPhase II
  • baxdrostataldosterone synthase inhibitor / small molecule / Cardiovascular, Renal and Metabolism
    hypertensionPhase IIIAcceptedprimary aldosteronismPhase III
  • baxdrostat/dapagliflozinaldosterone synthase inhibitor + SGLT2 inhibitor / small molecule combination / Cardiovascular, Renal and Metabolism
    CKD; prevention of heart failurePhase III
  • laroprovstatPCSK9 inhibitor / small molecule / Cardiovascular, Renal and Metabolism
    dyslipidaemiaPhase III
  • WainuaWainua / ligand-conjugated antisense / antisense oligonucleotide / Cardiovascular, Renal and Metabolism
    ATTRv-PNPhase IIILaunchedATTR CMLCM
  • zibotentan/dapagliflozinendothelin A receptor antagonist/SGLT2 inhibitor / small molecule combination / Cardiovascular, Renal and Metabolism
    CKD with high proteinuriaPhase III
  • elecoglipronoral GLP-1 receptor agonist / small molecule / Cardiovascular, Renal and Metabolism
    T2D/chronic weight managementPhase II
  • AZD6234AZD6234 / peptide / peptide / Cardiovascular, Renal and Metabolism
    chronic weight management in overweight or obesityPhase II
  • tozorakimabIL-33 mAb / monoclonal antibody / Respiratory & Immunology
    COPDPhase IIIsevere viral lower respiratory tract diseasePhase IIIasthmaPhase II
  • TezspireTezspire / TSLP mAb / monoclonal antibody / Respiratory & Immunology
    severe uncontrolled asthmaPhase IIILaunchedChinaeosinophilic esophagitis; COPD; nasal polypsLCM
  • SaphneloSaphnelo / type I IFN receptor mAb / monoclonal antibody / Respiratory & Immunology
    systemic lupus erythematosusPhase IIILaunchedChinacutaneous lupus erythematosus; SLE SCLCM
  • anselamimabfibril-reactive mAb / monoclonal antibody / Rare Disease
    amyloid light-chain amyloidosisPhase IIISubmitted
  • cliramitugtransthyretin depleter / large molecule / Rare Disease
    transthyretin amyloid cardiomyopathyPhase III
  • efzimfotase alfanext generation TNSALP ERT / enzyme replacement therapy / Rare Disease
    hypophosphatasiaPhase III
  • eneboparatideparathyroid hormone receptor 1 / large molecule / Rare Disease
    hypoparathyroidismPhase III
  • gefurulimabanti-C5 dual-binding nanobody / nanobody / Rare Disease
    generalised myasthenia gravisPhase IIISubmitted
  • KavigaleKavigale / SARS-CoV-2 LAAB / long-acting antibody / Infectious Disease
    prevention of COVID-19Phase IIILaunched
  • AZD0292AZD0292 / pseudomonas Psl-PcrV bispecific mAb / bispecific antibody / Infectious Disease
    bronchiectasisPhase II
  • AZD5148AZD5148 / anti-Clostridioides difficile TcdB mAb / monoclonal antibody / Infectious Disease
    reduction of C. diff recurrencePhase II
  • AZD7760AZD7760 / S. aureus virulence factors / mAb combination / Infectious Disease
    prevention of Staph aureus infectionPhase II

Amgen Inc.

amgenpipeline.com
30assets
  • erenumab-aooeAIMOVIG / CGRP receptor / Monoclonal antibody / Neuroscience
    Pediatric migraineInvestigational
  • blinatumomabBLINCYTO / CD19 x CD3 / BiTE molecule / Hematology/Oncology; Inflammation
    Newly diagnosed B-cell precursor acute lymphoblastic leukemiaInvestigationalRelapsed/refractory acute lymphoblastic leukemia, subcutaneous administrationPhase 2InvestigationalSystemic lupus erythematosus with and without nephritisInvestigational
  • dazodalibepCD40L / Fusion protein / Rare Disease
    Sjögren’s diseaseInvestigational
  • romosozumab-aqqgEVENITY / Sclerostin / Monoclonal antibody / Bone
    Pediatric osteogenesis imperfectaInvestigational
  • tarlatamab-dlleIMDELLTRA / DLL3 x CD3 / BiTE molecule / Hematology/Oncology
    Small cell lung cancer, limited-stage and extensive-stage settingsInvestigationalSmall cell lung cancer, combination studiesInvestigationalSmall cell lung cancer, subcutaneous administrationPhase 1Investigational
  • pegloticaseKRYSTEXXA / Uric acid / PEGylated uricase / Rare Disease
    Uncontrolled gout, subcutaneous administration with methotrexateInvestigational
  • sotorasibLUMAKRAS / KRAS G12C / Small molecule / Hematology/Oncology
    KRAS G12C-mutated metastatic colorectal cancer, first line combinationInvestigationalPreviously treated advanced KRAS G12C-mutated non-small cell lung cancerInvestigationalNewly diagnosed advanced KRAS G12C-mutated NSCLC, combinationInvestigational
  • maridebart cafraglutideAMG 133 / MariTide / GLP-1 receptor; GIP receptor / Antibody-peptide conjugate / Cardiometabolic; Diabetes
    ObesityInvestigationalCardiovascular risk reduction in ASCVD with obesity or overweightInvestigationalHeart failure events and cardiovascular risk reduction in HFpEF/HFmrEF with obesityInvestigational
  • romiplostimNPLATE / Thrombopoietin receptor / Peptibody / Hematology/Oncology
    Chemotherapy-induced thrombocytopeniaInvestigational
  • olpasiranAMG 890 / Lp(a) / siRNA / Cardiometabolic
    Atherosclerotic cardiovascular diseaseInvestigational
  • apremilastOTEZLA / PDE4 / Small molecule / Inflammation
    Juvenile psoriatic arthritisInvestigationalPediatric Behcet’s diseaseInvestigational
  • etelcalcetidePARSABIV / Calcium-sensing receptor / Peptide / Nephrology
    Pediatric secondary hyperparathyroidism in CKD receiving hemodialysisInvestigational
  • evolocumabREPATHA / PCSK9 / Monoclonal antibody / Cardiometabolic
    Hypercholesterolemia in high cardiovascular risk without prior MI or strokeInvestigational
  • avacopanTAVNEOS / C5aR1 / Small molecule / Rare Disease
    Pediatric ANCA-associated vasculitisInvestigational
  • teprotumumab-trbwTEPEZZA / IGF-1R / Monoclonal antibody / Rare Disease
    Thyroid eye disease, subcutaneous administrationInvestigational
  • tezepelumab-ekkoTEZSPIRE / TSLP / Monoclonal antibody / Inflammation
    Chronic obstructive pulmonary diseaseInvestigationalEosinophilic esophagitisInvestigational
  • xaluritamigAMG 509 / STEAP1 x CD3 / XmAb bispecific T-cell engager antibody / Hematology/Oncology
    Prostate cancerInvestigationalEwing sarcomaInvestigational
  • ABP 206ABP 206 / PD-1 / Monoclonal antibody biosimilar / Hematology/Oncology
    Investigational biosimilar to OPDIVO (nivolumab)Investigational biosimilar
  • ABP 234ABP 234 / PD-1 / Monoclonal antibody biosimilar / Hematology/Oncology
    Investigational biosimilar to KEYTRUDA (pembrolizumab)Investigational biosimilar
  • ABP 692ABP 692 / CD20 / Monoclonal antibody biosimilar / Inflammation
    Investigational biosimilar to OCREVUS (ocrelizumab)Investigational biosimilar
  • daxdilimabILT7 / Monoclonal antibody / Rare Disease
    Dermatomyositis and anti-synthetase inflammatory myositisInvestigationalDiscoid lupus erythematosusInvestigational
  • inebilizumabUPLIZNA / CD19 / Monoclonal antibody / Inflammation
    Systemic lupus erythematosus with nephritisInvestigational
  • carfilzomibKYPROLIS / Proteasome / Small molecule / Hematology/Oncology
    Pediatric acute lymphoblastic leukemiaInvestigational
  • AMG 104AMG 104 / TSLP / Monoclonal antibody Fab / Inflammation
    AsthmaInvestigational
  • AMG 732AMG 732 / IGF-1R / Monoclonal antibody / Rare Disease
    Thyroid eye diseaseInvestigational
  • AMG 355AMG 355 / CCR8 / Monoclonal antibody / Hematology/Oncology
    Advanced solid tumor malignanciesInvestigational
  • AMG 410AMG 410 / Small molecule / Hematology/Oncology
    Solid tumorsInvestigational
  • AMG 436AMG 436 / Small molecule / Hematology/Oncology
    Advanced solid tumor malignanciesInvestigational
  • AMG 513AMG 513 / Cardiometabolic
    ObesityInvestigational
  • AMG 691AMG 691 / Monoclonal antibody / Inflammation
    AsthmaInvestigational

Novo Nordisk A/S

novonordisk.com
30assets
  • Glucose sensitive insulinNN1845 / Analogue / Diabetes
    Type 1 and 2 diabetesPhase 1
  • Ventus NLRP3iNN6022 / NLRP3 / Inhibitor / Diabetes
    CVDPhase 1
  • siRNA GalXC-GYS2siRNA / Diabetes
    siRNA GalXC-GYS2Phase 1
  • CNPCNP / Analogue / Diabetes
    Heart failurePhase 1
  • Amylin 355Analogue / Obesity
    ObesityPhase 1
  • Amylin 1213Analogue / Obesity
    ObesityPhase 1
  • SLC25A5SLC25A5 / siRNA / Obesity
    MASHPhase 1
  • Inno8Antibody fragment / Rare Blood Disorders
    HaemophiliaPhase 1
  • Subcutaneous ZenagamtideGLP-1 / amylin / Co-agonist / Diabetes / Obesity
    Subcutaneous ZenagamtidePhase 2ObesityPhase 2
  • Monlunabant in DKDCB1 receptor / Small molecule / Diabetes
    Diabetic Kidney Disease (DKD)Phase 2
  • Oral ZenagamtideGLP-1 / amylin / Co-agonist / Diabetes / Obesity
    DiabetesPhase 2ObesityPhase 2
  • CDR132LmiR-132 / Antisense oligonucleotide / Diabetes
    Heart failure with reduced ejection fraction (HFrEF)Phase 2
  • UBT251 (GGG tri-agonist)Obesity
    ObesityPhase 2
  • TripleGLP1 / GIP / amylin / Tri-agonist / Obesity
    ObesityPhase 2
  • MonlunabantINV-202 / CB1 receptor / Small molecule / Obesity
    ObesityPhase 2
  • NDecEPI01 / Rare Blood Disorders
    Sickle cell disease / An oral combination of decitabine and tetrahydrouridine. Project is developed in collaboration with EpiDestiny.Phase 2
  • EtavopivatRare Blood Disorders
    ThalassemiaPhase 2
  • CagriSema in T2DNN9388 / Analogue / Diabetes
    Type 2 diabetesPhase 3
  • Ziltivekimab ASCVDNN6018 / Diabetes
    Atherosclerotic cardiovascular disease (ASCVD) with chronic kidney disease (CKD) and inflammationPhase 3
  • CoramitugPRX004 / Diabetes
    ATTR CardiomyopathyPhase 3
  • Ziltivekimabin HFpEFDiabetes
    Heart failure with preserved ejection fraction (HFpEF)Phase 3
  • Ziltivekimab AMIDiabetes
    Acute Myocardial infarction (AMI)Phase 3
  • CagrilintideAnalogue / Obesity
    ObesityPhase 3
  • Efruxifermin in MASHFGF21 / Analogue / Obesity
    MASHPhase 3
  • Etavopivat (Sickle Cell Disease)Small molecule / Rare Blood Disorders
    Sickle Cell DiseasePhase 3
  • IcosemaNN1535 / Analogue / Diabetes
    Type 2 diabetes / A combination of GLP-1 analogue semaglutide and insulin icodec intended for once-weekly treatment.Filed
  • Insulin icodecNN1436 / Analogue / Diabetes
    DiabetesFiled
  • CagriSemaNN9898 / Analogue / Obesity
    ObesityFiled
  • Semaglutide 7.2 mgAnalogue / Obesity
    ObesityFiled
  • DenecimigMim8 / Inhibitor / Rare Blood Disorders
    Haemophilia A with or without inhibitors / A next generation FVIII mimetic bispecific antibody for subcutaneous prophylaxis of haemophilia A regardless of inhibitor status.Filed

GSK

gsk.com
26assets
  • ArexvyArexvy / RSV F protein / Recombinant protein, adjuvanted vaccine / Infectious diseases
    RSV adults (50-59 years of age at increased risk)Phase III/Registration
  • gepotidacinGSK2140944 / Bacterial topoisomerase inhibitor / Small molecule / Infectious diseases
    Urogenital gonorrhoeaPhase III/Registration
  • bepirovirsenGSK3228836 / HBsAg / Antisense oligonucleotide / Infectious diseases
    Chronic HBV infectionPhase III
  • BexseroBexsero / MenB / Recombinant protein, OMV vaccine / Infectious diseases
    Meningitis B (infants US)Phase III/RegistrationUS
  • MenABCWY vaccineGSK3536819 / Meningococcal ABCWY / Recombinant protein, OMV, conjugated vaccine / Infectious diseases
    Meningococcal diseasePhase III/Registration
  • Nucala (mepolizumab)Nucala / IL-5 / Monoclonal antibody / Respiratory/Immunology
    COPD with eosinophilic phenotypePhase III/Registration
  • depemokimabGSK3511294 / IL-5 / Monoclonal antibody / Respiratory/Immunology
    Asthma with type 2 inflammationPhase III/RegistrationChronic rhinosinusitis with nasal polypsPhase III/RegistrationEGPAPhase III
  • camlipixantGSK4523199 / P2X3 / Small molecule antagonist / Respiratory/Immunology
    Refractory chronic coughPhase III
  • linerixibatGSK2330672 / IBAT / Small molecule / Respiratory/Immunology
    Cholestatic pruritus in primary biliary cholangitisPhase III
  • Blenrep (belantamab mafodotin)GSK2857916 / Blenrep / BCMA / Antibody-drug conjugate / Oncology
    Relapsed/refractory multiple myelomaPhase III/Registration
  • Jemperli (dostarlimab)Jemperli / PD-1 / Monoclonal antibody / Oncology
    Endometrial cancerPhase III/RegistrationRectal cancer (dMMR)Phase IINon-small cell lung cancerPhase III
  • Zejula (niraparib)Zejula / PARP / Small molecule / Oncology
    Ovarian cancerPhase III/Registration
  • belrestotugGSK4428859 / TIGIT / Monoclonal antibody / Oncology
    NSCLC and other solid tumorsPhase III
  • GSK5764227GSK5764227 / B7-H3 / Antibody-drug conjugate / Oncology
    Extensive-stage small-cell lung cancerPhase IIIAdvanced GI solid tumorsPhase I/II
  • cobolimabGSK4069889 / TIM-3 / Monoclonal antibody / Oncology
    Non-small cell lung cancerPhase II/III
  • GSK4532990GSK4532990 / HSD17B13 / RNA interference / Opportunity driven
    NASH/MASHPhase II
  • GSK4172239GSK4172239 / DNMT1 / Small molecule inhibitor / Opportunity driven
    Sickle cell diseasePhase I
  • GSK3882347GSK3882347 / FimH / Small molecule antagonist / Infectious diseases
    Uncomplicated UTIPhase I
  • GSK3923868GSK3923868 / PI4K beta / Small molecule inhibitor / Infectious diseases
    Rhinovirus diseasePhase I
  • GSK3965193GSK3965193 / PAPD5/PAPD7 / Small molecule inhibitor / Infectious diseases
    Chronic HBV infectionPhase I
  • GSK2556286GSK2556286 / Mtb cholesterol-dependent / Small molecule inhibitor / Infectious diseases
    TuberculosisPhase I
  • GSK3772701GSK3772701 / P. falciparum whole cell / Small molecule inhibitor / Infectious diseases
    MalariaPhase I
  • GSK4024484GSK4024484 / P. falciparum whole cell / Small molecule inhibitor / Infectious diseases
    MalariaPhase I
  • GSK3536867GSK3536867 / Salmonella typhoid + paratyphoid A / Bivalent conjugate vaccine / Infectious diseases
    Salmonella (typhoid + paratyphoid A)Phase I
  • latiglutenase / AMG 133-like programs
  • AGN-151586 / progranulin program (latozinemab)AL001 / Progranulin/sortilin / Monoclonal antibody / Opportunity driven
    Frontotemporal dementia with progranulin gene mutationPhase III

BeOne Medicines Ltd.

beonemedicines.com
26assets
  • ZanubrutinibBTK / Inhibitor / Hematologic Malignancies / Immunology & Inflammation
    Treatment-Naive Chronic Lymphocytic Leukemia / Small Lymphocytic LymphomaApprovedRelapsed/Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic LymphomaApprovedRelapsed/Refractory Waldenström Macroglobulinemia and Treatment-Naïve Waldenström MacroglobulinemiaApproved
  • SonrotoclaxBCL2 / Inhibitor / Hematologic Malignancies
    Treatment-Naive Chronic Lymphocytic LeukemiaPhase 3Treatment-Naive Chronic Lymphocytic LeukemiaPhase 3Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaApproved
  • TislelizumabPD-1 / Monoclonal Antibody / Lung Cancers / Gastrointestinal Cancers / Other Cancers
    First-Line Extensive-Stage Small Cell Lung CancerApprovedFirst-Line Non-Squamous Non-Small Cell Lung CancerApprovedFirst-Line Squamous Non-Small Cell Lung CancerApproved
  • BGB-16673BTK Chimeric Degradation Activation Compound [CDAC] / Hematologic Malignancies / Immunology & Inflammation
    Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaPhase 3Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaPhase 3Relapsed/Refractory Mantle Cell LymphomaPhase 2
  • BlinatumomabCD19 x CD3 / BiTE® [Bispecific T-Cell Engager] / Hematologic Malignancies
    Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (subcutaneous formulation)Phase 2
  • TarlatamabDLL3 x CD3 / BiTE® [Bispecific T-cell Engager] / Lung Cancers
    First-Line Extensive-Stage Small Cell Lung CancerPhase 3First-Line Extensive-Stage Small Cell Lung CancerPhase 3Second-Line Small Cell Lung CancerPhase 3
  • ZanidatamabHER2 Bispecific / Antibody / Gastrointestinal Cancers
    First-Line HER2 Positive Gastroesophageal AdenocarcinomaPhase 3Second-Line HER2 Positive Biliary Tract CancerApprovedFirst-Line HER2 positive Biliary Tract CancerPhase 3
  • BG-68501CDK2 / Inhibitor / Breast/Gynecologic Cancers
    Breast Cancer and Solid TumorsPhase 1
  • BGB-21447BCL2 / Inhibitor / Breast/Gynecologic Cancers
    Hormone Receptor Positive Breast CancerPhase 1
  • BGB-43395CDK4 / Inhibitor / Breast/Gynecologic Cancers
    Breast Cancer and Solid TumorsPhase 1
  • BGB-B455Claudin 6 x CD3 Bispecific / Antibody / Breast/Gynecologic Cancers
    Gynecologic and Solid TumorsPhase 1
  • BG-C9074B7-H4 Antibody Drug Conjugate / Breast/Gynecologic Cancers
    Breast Cancer and Solid TumorsPhase 1
  • BG-75202KAT6A/B / Inhibitor / Breast/Gynecologic Cancers
    Breast CancerPhase 1
  • BG-75098CDK2 Chimeric Degradation Activation Compound [CDAC] / Breast/Gynecologic Cancers
    Breast CancerPhase 1
  • BGB-B2033GPC3 x 4-1BB Bispecific / Antibody / Gastrointestinal Cancers
    Solid TumorsPhase 1
  • BG-C137FGFR2b Antibody Drug Conjugate / Gastrointestinal Cancers
    Gastrointestinal CancersPhase 1
  • BGB-53038Pan-KRAS / Inhibitor / Gastrointestinal Cancers
    Lung Cancers and GI CancersPhase 1
  • BG-C477CEA Antibody Drug Conjugate / Gastrointestinal Cancers
    Lung Cancers and GI CancersPhase 1
  • BG-C0902EGFR x MET x MET Antibody Drug Conjugate / Lung Cancers
    Lung Cancers and GI CancersPhase 1
  • BG-T187EGFR x MET x MET Trispecific / Antibody / Lung Cancers
    Lung Cancers and GI CancersPhase 1
  • BGB-58067MTA Cooperative PRMT5 / Inhibitor / Lung Cancers
    Lung Cancers and GI CancersPhase 1
  • BG-89894MAT2A / Inhibitor / Lung Cancers
    Lung Cancers and Solid TumorsPhase 1
  • BG-60366EGFR Chimeric Degradation Activation Compound [CDAC] / Lung Cancers
    Lung CancersPhase 1
  • BGB-26808HPK1 / Inhibitor / Gastrointestinal Cancers
    Solid Tumors/Pan- TumorPhase 1
  • XaluritamigSTEAP1 x CD3 Bispecific T-cell Engager (XmAb®) / Other Cancers
    Metastatic Castration-Resistant Prostate CancerPhase 1
  • BGB-45035IRAK4 Chimeric Degradation Activation Compound [CDAC] / Immunology & Inflammation
    Rheumatoid ArthritisPhase 2Skin DiseasesPhase 1

Alnylam Pharmaceuticals, Inc.

alnylam.com
24assets
  • NucresiranRNAi therapeutic / Transthyretin Amyloidosis (TTR)
    ATTR Amyloidosis with CardiomyopathyPhase 3hATTR Amyloidosis with PolyneuropathyPhase 3
  • ZilebesiranRNAi therapeutic / Cardiovascular
    HypertensionPhase 3REVERSIR HypertensionPhase 1
  • RapirosiranALN-HSD / HSD / RNAi therapeutic / Metabolic
    Metabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 2
  • ALN-ANG3ALN-ANG3 / ANG3 / RNAi therapeutic / Metabolic
    Diabetic Kidney DiseasePhase 2
  • ALN-4324ALN-4324 / GRB14 / RNAi therapeutic / Metabolic
    Type 2 Diabetes MellitusPhase 1
  • ALN-2232ALN-2232 / ACVR1C / RNAi therapeutic / Metabolic
    Obesity & Weight ManagementPhase 1
  • ALN-PNPALN-PNP / PNP / RNAi therapeutic / Metabolic
    Non-Alcoholic Fatty Liver Disease (NAFLD)Phase 1
  • ALN-APOC3ALN-APOC3 / APOC3 / RNAi therapeutic / Metabolic
    DyslipidemiaPhase 1
  • ALN-CIDEBALN-CIDEB / CIDEB / RNAi therapeutic / Metabolic
    Metabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 1
  • Cemdisiran(+/- Pozelimab)RNAi therapeutic / Neuroscience/Other
    Myasthenia GravisPhase 3Geographic AtrophyPhase 3
  • MivelsiranALN-APP / APP / RNAi therapeutic / Neuroscience
    Cerebral Amyloid Angiopathy (CAA)Phase 2Alzheimer’s DiseasePhase 1
  • ALN-HTT02ALN-HTT02 / HTT / RNAi therapeutic / Neuroscience
    Huntington’s DiseasePhase 1
  • ALN-5288ALN-5288 / MAPT / RNAi therapeutic / Neuroscience
    Alzheimer’s DiseasePhase 1
  • ALN-SODALN-SOD / SOD1 / RNAi therapeutic / Neuroscience
    SOD1 Amyotrophic Lateral Sclerosis (ALS)Phase 1
  • ALN-SNCAALN-SNCA / SNCA / RNAi therapeutic / Neuroscience
    Parkinson’s DiseasePhase 1
  • Cemdisiran (+Pozelimab)RNAi therapeutic / Hematology
    Paroxysmal Nocturnal HemoglobinuriaPhase 3
  • ALN-6400ALN-6400 / PLG / RNAi therapeutic / Hematology
    Bleeding DisordersPhase 2
  • AG-236ALN-TMP / TMP / RNAi therapeutic / Hematology
    Polycythemia VeraPhase 1
  • ALN-CFBALN-CFB / CFB / RNAi therapeutic / Hematology
    Paroxysmal Nocturnal HemoglobinuriaPhase 1
  • Elebsiran (+Tobevibart)RNAi therapeutic / Other
    Hepatitis D Virus InfectionPhase 2
  • ALN-BCATALN-BCAT / BCAT / RNAi therapeutic / Other
    Hepatocellular CarcinomaPhase 1
  • ALN-4285ALN-4285 / RNAi therapeutic / Other
    Healthy VolunteersPhase 1
  • ALN-4915ALN-4915 / RNAi therapeutic / Other
    Healthy VolunteersPhase 1
  • ALN-F1202ALN-F1202 / RNAi therapeutic / Other
    Healthy VolunteersPhase 1

BioNTech SE

biontech.com
21assets
  • PumitamigPD-L1/VEGF-A / immunomodulator / Oncology
    Multiple solid tumors; NSCLC; SCLC; HCC; CRC; ES-SCLC; EGFRm NSCLC; glioblastoma; MPM; NEN; TNBC; PDACclinical
  • BNT325/DB-1305BNT325/DB-1305 / targeted therapy / Oncology
    Multiple solid tumorsclinical
  • BNT324/DB-1311BNT324/DB-1311 / targeted therapy / Oncology
    Multiple solid tumorsclinical
  • BNT321BNT321 / targeted therapy / Oncology
    Multiple solid tumors; HCC combinationclinical
  • Autogene cevumeranmRNA cancer immunotherapy / Oncology
    Adjuvant CRC; adjuvant PDACclinical
  • BNT116BNT116 / mRNA cancer immunotherapy / Oncology
    Advanced NSCLC; 1L advanced NSCLCclinical
  • BNT113BNT113 / HPV16 / mRNA cancer immunotherapy / Oncology
    1L HPV16+ HNSCCclinical
  • GotistobartCTLA-4 / immunomodulator / Oncology
    Metastatic NSCLC; metastatic CRPC; PROC; multiple solid tumorsclinical
  • BNT211BNT211 / cell therapy / Oncology
    Multiple solid tumorsclinical
  • BNT314/GEN1059BNT314/GEN1059 / immunomodulator / Oncology
    Multiple solid tumors; metastatic CRC combinationclinical
  • BNT329BNT329 / immunomodulator / Oncology
    Multiple solid tumorsclinical
  • BNT326/YL202BNT326/YL202 / targeted therapy / Oncology
    Multiple solid tumors; NSCLC combination; advanced/metastatic breast cancerclinical
  • BNT317BNT317 / immunomodulator / Oncology
    Multiple solid tumorsclinical
  • Trastuzumab pamirtecanHER2 / targeted therapy / Oncology
    Metastatic breast cancer; advanced/metastatic breast cancer combination; 2L endometrial cancer; multiple solid tumorsclinical
  • BNT162 + BNT161BNT162 + BNT161 / mRNA vaccine combination / Infectious diseases
    COVID-19-influenza combinationclinical
  • BNT163BNT163 / HSV / mRNA vaccine / Infectious diseases
    HSVclinical
  • BNT166BNT166 / Mpox / mRNA vaccine / Infectious diseases
    Mpoxclinical
  • BNT162BNT162 / COMIRNATY / SARS-CoV-2 / mRNA vaccine / Infectious diseases
    COVID-19Commercialmarketed
  • BNT351BNT351 / HIV / antibody mRNA / Infectious diseases
    HIVclinical
  • BNT164BNT164 / Tuberculosis / mRNA vaccine / Infectious diseases
    Tuberculosisclinical
  • BNT165BNT165 / Malaria / mRNA vaccine / Infectious diseases
    Malariaclinical

Gilead Sciences, Inc.

gilead.com
19assets
  • LenacapavirHIV capsid inhibitor / Long-acting injectable / Virology
    HIV Prevention (PrEP, PURPOSE 365)Phase 3HIV Treatment (in combinations)Phase 3HIV Treatment (with bNAbs)Phase 2
  • Bictegravir/lenacapavir oral combinationINSTI + capsid inhibitor / Oral / Virology
    HIV Treatment (virologically suppressed, ARTISTRY-1 & ARTISTRY-2)Phase 3
  • Islatravir/lenacapavir oral combinationLong-acting oral / Virology
    HIV Treatment (virologically suppressed, ISLEND-1 & ISLEND-2)Phase 3
  • Lenacapavir + teropavimab + zinlirvimabCapsid + bNAbs / Long-acting injectable / Virology
    HIV Treatment (virologically suppressed)Phase 2
  • GS-1720/GS-4182GS-1720/GS-4182 / INSTI/capsid inhibitor / Long-acting oral / Virology
    HIV Treatment (WONDERS-1 & -2)Phase 2
  • Teropavimab + zinlirvimabbNAbs / Broadly neutralizing antibodies / Virology
    HIV CurePhase 2
  • VesatolimodVirology
    HIV Cure (FRESH)Phase 2
  • SelgantolimodVirology
    HBV CurePhase 2
  • HepcludexHepcludex / Virology
    Chronic HDV with compensated liver disease (MYR301)FiledBLA pending (US); Approved (EU)USEU
  • EdecesertibInflammation
    Lupus (COSMIC)Phase 2
  • Tilpisertib fosmecarbilInflammation
    Inflammatory bowel disease (PALEKONA)Phase 2
  • α4β7 inhibitorα4β7 / Inflammation
    Inflammatory Bowel Disease (SWIFT)Phase 2
  • Sacituzumab govitecan-hziyAntibody-drug conjugate / Oncology
    1L metastatic triple-negative breast cancer (PD-L1-, ASCENT-03)FiledsBLA pendingUS1L metastatic triple-negative breast cancer (PD-L1+, with pembrolizumab, ASCENT-04)FiledsBLA pendingUSHigh risk adjuvant triple-negative breast cancer (with pembrolizumab, ASCENT-05)Phase 3
  • Axicabtagene ciloleucelCD19 CAR / Cell therapy / Oncology
    2L+ high-risk follicular lymphoma (ZUMA-22)Phase 31L high-risk large B-cell lymphoma (ZUMA-23)Phase 3
  • Brexucabtagene autoleucelCD19 CAR / Cell therapy / Oncology
    Pediatric acute lymphocytic leukemia/non-Hodgkin lymphoma (ZUMA-4)Phase 2
  • Anitocabtagene autoleucelCell therapy / Oncology
    2-4L relapsed/refractory multiple myeloma (iMMagine-3)Phase 34L+ relapsed/refractory multiple myeloma (iMMagine-1)FiledBLA pendingUS
  • KITE-363KITE-363 / CD19/CD20 bicistronic / Cell therapy / Oncology
    Relapsed/refractory diffuse large B-cell lymphomaPhase 1RMAT designationRheumatology (autoimmune)Phase 1
  • DenikitugGS-1811 / Oncology
    Advanced cancersPhase 1
  • Domvanalimab + zimberelimabAnti-TIGIT + anti-PD1 / Combination therapy / Oncology
    1L metastatic non-small cell lung cancer (with chemo, STAR-121)Phase 31L head and neck squamous cell carcinoma (VELOCITY-HNSCC)Phase 2

Ionis Pharmaceuticals, Inc.

ionis.com
19assets
  • ZilganersenION373 / GFAP / RNA-Targeted Therapeutic / Neurology
    Alexander DiseasePhase 1/3ActiveGlobal
  • ION582ION582 / UBE3A-ATS / RNA-Targeted Therapeutic / Neurology
    Angelman SyndromeClinicalActive
  • ION269ION269 / APP / RNA-Targeted Therapeutic / Neurology
    Alzheimer's DiseaseClinicalActive
  • ION717ION717 / PRNP / RNA-Targeted Therapeutic / Neurology
    Prion DiseaseClinicalActive
  • ION356ION356 / PLP1 / RNA-Targeted Therapeutic / Neurology
    Pelizaeus-Merzbacher DiseaseClinicalActive
  • ION859ION859 / LRRK2 / RNA-Targeted Therapeutic / Neurology
    Parkinson's DiseaseClinicalActive
  • ION464ION464 / SNCA / RNA-Targeted Therapeutic / Neurology
    Multiple System AtrophyClinicalActiveParkinson's DiseaseClinicalActive
  • ION440ION440 / MECP2 / RNA-Targeted Therapeutic / Neurology
    MECP2 Duplication SyndromeClinicalActive
  • OlezarsenApoC-III / RNA-Targeted Therapeutic / Cardiology
    Severe HypertriglyceridemiaClinicalActive
  • DonidalorsenPKK / RNA-Targeted Therapeutic / Specialty/Rare
    Hereditary AngioedemaClinicalActive
  • SapablursenTMPRSS6 / RNA-Targeted Therapeutic / Specialty/Rare
    Polycythemia VeraClinicalActive
  • UlefnersenFUS / RNA-Targeted Therapeutic / Neurology
    Amyotrophic Lateral SclerosisClinicalActive
  • TofersenSOD1 / RNA-Targeted Therapeutic / Neurology
    Amyotrophic Lateral Sclerosis (Presymptomatic SOD1)ClinicalActive
  • IONIS-MAPTRxBIIB080 / TAU / RNA-Targeted Therapeutic / Neurology
    Alzheimer's DiseaseClinicalActive
  • TominersenIONIS-HTTRx / HTT / RNA-Targeted Therapeutic / Neurology
    Huntington's DiseasePhase 2Active
  • ION306ION306 / SMN2 / RNA-Targeted Therapeutic / Neurology
    Spinal Muscular AtrophyClinicalActive
  • EplontersenTTR / RNA-Targeted Therapeutic / Cardiology
    Transthyretin-Mediated Amyloid CardiomyopathyPhase 3Active
  • ION904ION904 / Angiotensinogen / RNA-Targeted Therapeutic / Cardiology
    Treatment-Resistant HypertensionClinicalActive
  • BepirovirsenHepatitis B Virus / RNA-Targeted Therapeutic / Other Medicines
    Hepatitis B Virus InfectionPhase 3Active

Astellas Pharma Inc.

astellas.com
18assets
  • zolbetuximabIMAB362 / VYLOY / Claudin 18.2 / Antibody / Oncology
    Gastric and gastroesophageal junction adenocarcinoma, combo with pembrolizumab and chemotherapyFiledEuropeJapan
  • gilteritinibASP2215 / XOSPATA / FLT3 / Small molecule / Oncology
    Newly diagnosed acute myeloid leukemia with high intensity induction chemotherapyPhase 3Post-chemotherapy maintenance acute myeloid leukemiaPhase 3Post-hematopoietic stem cell transplant maintenance acute myeloid leukemiaPhase 3
  • enfortumab vedotinASG-22ME / PADCEV / Nectin-4 / Antibody-drug conjugate (ADC) / Oncology
    Cisplatin-eligible muscle-invasive bladder cancer, combo with pembrolizumabFiledEuropeUSCisplatin-ineligible muscle-invasive bladder cancer, combo with pembrolizumabFiledEuropeJapanBladder-sparing muscle-invasive bladder cancer, combo with pembrolizumabPhase 2
  • fezolinetantESN364 / VEOZAH / NK3 receptor / Small molecule / Women's Health
    Vasomotor symptoms due to menopausePhase 3ChinaVasomotor symptoms in breast cancer patients on adjuvant endocrine therapyPhase 2
  • zocaglusagene nuzaparvovecAT845 / GAA gene replacement / Gene therapy (AAV-based gene therapy) / Genetic Regulation
    Pompe diseasePhase 1
  • ASP2957ASP2957 / MTM1 gene replacement / Gene therapy (AAV-based gene therapy) / Genetic Regulation
    X-linked myotubular myopathyPhase 1
  • setidegrasibKRAS G12D / Small molecule degrader / Targeted Protein Degradation
    Pancreatic ductal adenocarcinomaPhase 3
  • ASP7317ASP7317 / Retinal pigment epithelial cells / Cell therapy / Ophthalmology
    Geographic atrophy secondary to age-related macular degenerationPhase 1
  • ASP1002ASP1002 / Claudin 4/CD137 / T-cell engager bispecific antibody / Oncology
    Gastric and gastroesophageal junction adenocarcinoma; pancreatic adenocarcinomaPhase 1
  • ASP5834ASP5834 / Pan-KRAS / Small molecule degrader / Oncology
    CancerPhase 1
  • VIR-5500VIR-5500 / PSMA/CD3 / T-cell engager / Oncology
    Prostate cancerPhase 1
  • ASP2998ASP2998 / TROP2 / Antibody-drug conjugate (ADC) / Oncology
    CancerPhase 1
  • ASP2138ASP2138 / Claudin 18.2/CD3 / T-cell engager bispecific antibody / Oncology
    CancerPhase 2
  • ASP546CASP546C / Claudin 18.2 / Antibody-drug conjugate (ADC) / Oncology
    CancerPhase 2Europe
  • abiraterone decanoateASP5541/PRL-02 / CYP17 lyase / Small molecule / Oncology
    Prostate cancerPhase 2
  • mirabegronYM178 / Beta-3 receptor / Small molecule / Urology
    Neurogenic detrusor overactivity in pediatric patients aged 6 months to less than 3 yearsPhase 3Europe
  • roxadustatASP1517/FG-4592 / HIF-PH / Small molecule / Nephrology
    Anemia associated with chronic kidney disease in pediatric patientsPhase 3Europe
  • pudexacianinium chlorideASP5354 / Drug-device combination / Other
    Intraoperative ureter visualization for minimally invasive and open abdominopelvic surgeriesPhase 3

Amneal Pharmaceuticals, Inc.

amneal.com
18assets
  • Mesalamine DRAsacol HD / generic small molecule / Gastroenterology
  • EverolimusAfinitor / mTOR / generic small molecule / Oncology
  • Prednisolone acetatePred-Forte / generic small molecule / Ophthalmology
  • EltrombopagPromacta / TPO receptor agonist / generic small molecule / Hematology
  • EpinephrineAdrenalin / adrenergic receptors / generic small molecule / Emergency/Critical Care
  • LenalidomideRevlimid / generic small molecule / Oncology
  • Risperidone ERRisperdal Consta / dopamine/serotonin receptors / generic long-acting injectable / Psychiatry
  • Romidepsin injectionRomidepsin / HDAC / generic small molecule / Oncology
  • CyclosporineRestasis / calcineurin / generic small molecule / Ophthalmology
  • Beclomethasone dipropionateQVAR / glucocorticoid receptor / generic inhaled corticosteroid / Respiratory
  • Sodium BicarbonateNeut / generic injectable / Critical Care
  • Lanreotide injectionSomatuline Depot / somatostatin receptors / generic peptide injectable / Endocrinology/Oncology
  • RifaximinXifaxan / generic small molecule / Gastroenterology
  • Omalizumab biosimilarXOLAIR / IgE / biosimilar monoclonal antibody / Immunology/Allergy
  • Sodium oxybateXyrem / generic small molecule / Neurology
  • BimatoprostLumigan / prostaglandin receptor / generic small molecule / Ophthalmology
  • Denosumab biosimilarsPROLIA & XGEVA / RANKL / biosimilar monoclonal antibody / Osteoporosis/Bone Cancer
  • Albuterol sulfateProAir HFA / beta-2 adrenergic receptor / generic inhaled small molecule / Respiratory

Arrowhead Pharmaceuticals, Inc.

arrowheadpharma.com
18assets
  • PlozasiranARO-APOC3 / REDEMPLO / APOC3 / RNAi therapeutic / Cardiometabolic
    Familial chylomicronemia syndromeIn MarketSevere hypertriglyceridemiaPhase 3ActiveHypertriglyceridemiaPhase 3Active
  • ZodasiranARO-ANG3 / ANGPTL3 / RNAi therapeutic / Cardiometabolic
    Homozygous familial hypercholesterolemiaPhase 3Recruiting
  • OlpasiranAMG 890; ARO-LPA / LPA / RNAi therapeutic / Cardiovascular disease
    Elevated lipoprotein(a)/cardiovascular riskPhase 3Recruiting/Active
  • GSK4532990ARO-HSD / HSD17B13 / RNAi therapeutic / Liver disease
    MASH/NASHPhase 2Recruiting
  • ARO-PNPLA3JNJ-75220795 / PNPLA3 / RNAi therapeutic / Liver disease
    MASH/NASHPhase 1
  • ARO-INHBEINHBE/Activin E / RNAi therapeutic / Obesity/metabolic disease
    Obesity with or without type 2 diabetesPhase 1
  • ARO-ALK7ACVR1C/ALK7 / RNAi therapeutic / Obesity/metabolic disease
    Obesity with or without type 2 diabetesPhase 1Recruiting
  • ARO-MAPTMAPT/tau / RNAi therapeutic / CNS
    Alzheimer's diseasePhase 1Recruiting
  • ARO-ATXN2ATXN2 / RNAi therapeutic / CNS
    Spinocerebellar ataxia 2Phase 1
  • SRP-1005ARO-HTT / HTT / siRNA therapeutic / CNS
    Huntington's diseasePhase 1
  • ARO-RAGERAGE / RNAi therapeutic / Pulmonary
    Inflammatory pulmonary diseasesPhase 2Active
  • ARO-MMP7MMP7 / RNAi therapeutic / Pulmonary
    Idiopathic pulmonary fibrosisPhase 1
  • FazirsiranTAK-999; ARO-AAT / Z-AAT / RNAi therapeutic / Liver disease
    Alpha-1 antitrypsin deficiency-associated liver diseasePhase 3Recruiting
  • ARO-HBVJNJ-3989; JNJ-73763989 / HBV gene products / RNAi therapeutic / Infectious disease
    Chronic hepatitis BPhase 2
  • ARO-DUX4DUX4 / RNAi therapeutic / Muscular disease
    Facioscapulohumeral muscular dystrophyPhase 2
  • ARO-DM1DMPK mRNA / RNAi therapeutic / Muscular disease
    Myotonic dystrophy type 1Phase 2Recruiting
  • ARO-C3Complement component 3 / RNAi therapeutic / Complement mediated disease
    Complement-mediated renal diseasePhase 1RecruitingC3 glomerulopathyPhase 1RecruitingIgA nephropathyPhase 1Recruiting
  • ARO-CFBComplement factor B / RNAi therapeutic / Complement mediated disease
    Complement mediated diseasePhase 1

XOMA Royalty Corporation

xoma.com
18assets
  • Vabysmofaricimab-svoa / VABYSMO / VEGF/Ang-2 / Bispecific antibody / Ophthalmology
    Neovascular age-related macular degeneration (nAMD) and Diabetic macular edema (DME)Approvedapproved
  • Ojemdatovorafenib / OJEMDA / Oncology
    Oncology (undisclosed approved indication)Approvedapproved
  • Miplyffaarimoclomol / MIPLYFFA / Rare Diseases / Neurology
    Niemann-Pick disease type C (NPC)ApprovedapprovedUS
  • Xaciatoclindamycin phosphate vaginal gel 2% / XACIATO / Small molecule / Gynecology / Infectious Disease
    Bacterial VaginosisApprovedapproved
  • Ixinitycoagulation factor IX (recombinant) / IXINITY / Factor IX / Recombinant protein / Hematology
    Hemophilia BApprovedapproved
  • Dsuviasufentanil sublingual tablet / DSUVIA / Opioid receptor / Small molecule / Pain Management
    PainApprovedapproved
  • Dare to Playsildenafil cream / DARE to PLAY / PDE5 / Small molecule / Gynecology / Sexual Health
    Female Sexual Arousal DisorderApprovedapproved
  • ersodetugRZ358 / INSR / Antibody / Metabolic Disorders
    Hypoglycemia due to congenital hyperinsulinism (cHI)Phase 3ongoingHypoglycemia due to tumor hyperinsulinismPhase 3ongoing
  • RZ402RZ402 / Ophthalmology
    Diabetic macular edema (DME)Phase 2ongoing
  • D-FiFCX-007 / Gene Therapy / Dermatology / Rare Diseases
    Dystrophic epidermolysis bullosa (DEB)Phase 3ongoing
  • seralutinibGB002 / PDGFR, CSF1R, and c-KIT / Inhaled tyrosine kinase inhibitor / Respiratory / Cardiovascular
    Pulmonary arterial hypertension (PAH)Phase 3ongoingPulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Phase 2ongoing
  • cetrelimabJNJ-63723283 / PD-1 / Antibody / Oncology / Infectious Disease
    Muscle-invasive bladder cancer (MIBC)Phase 2ongoingChronic Hepatitis B Virus InfectionPhase 2ongoing
  • volixibatLUM-002 / Ileal bile acid transporter (IBAT) / Small molecule / Gastroenterology
    Primary sclerosing cholangitis (PSC)Phase 2bongoingPrimary biliary cholangitis (PBC)Phase 2ongoing
  • osavampatorNeurology / Psychiatry
    Major depressive disorderPhase 3ongoing
  • OHB-607OHB-607 / Recombinant human IGF-I/IGFBP-3 / Recombinant protein / Respiratory / Neonatology
    Prevention of bronchopulmonary dysplasia in extremely premature infantsPhase 2ongoing
  • REC-4881REC-4881 / Allosteric MEK1/2 / Small molecule / Oncology
    Familial adenomatous polyposisPhase 2ongoing
  • NIS793NIS793 / Antibody / Oncology
    Solid tumorsPhase 3ongoing
  • QTORIN rapamycinQTORIN / mTOR / Small molecule / Dermatology / Rare Diseases
    Cutaneous venous malformationsPhase 3ongoingClinically significant angiokeratomasPhase 2ongoing

Neurocrine Biosciences, Inc.

neurocrine.com
17assets
  • direclidineM4 / Small Molecule / Psychiatry
    SchizophreniaPhase 3Bipolar ManiaPhase 2
  • NBI-570M1/M4 / Small Molecule / Psychiatry
    SchizophreniaPhase 2
  • osavampatorAMPA / Small Molecule / Psychiatry
    Major Depressive DisorderPhase 3
  • NBI-986M4 / Small Molecule / Neurology
    Movement DisordersPhase 1
  • NBI-890VMAT2 / Small Molecule / Psychiatry
    Tardive DyskinesiaPhase 2
  • NBI-569M1/M4 / Small Molecule / Psychiatry
    Alzheimer's PsychosisPhase 1
  • NBI-567M1 / Small Molecule / Neurology
    Alzheimer's CognitionPhase 1
  • NBI-355Nav1.2/1.6 / Small Molecule / Neurology
    EpilepsyPhase 1
  • NBIP-1435CRF1 / Peptide / Endocrinology
    Classic Congenital Adrenal HyperplasiaPhase 1
  • NBIP-2118CRF2 / Peptide / Endocrinology
    ObesityPhase 1
  • NBIP-1968TG + NBIP-2118 Combo / Peptide / Endocrinology
    ObesityPhase 4
  • NBIB-223Frataxin / Gene Therapy / Neurology
    Friedreich's AtaxiaPhase 4
  • NBI-675VMAT2 / Small Molecule / Psychiatry
    CNS IndicationsPhase 1
  • NBI-188CRF1 / Small Molecule / Endocrinology
    Women's HealthPhase 4
  • NBIM-1748Immunology
    UndisclosedPhase 4
  • NBIM-1008Immunology
    UndisclosedPhase 4
  • NBIM-1112Immunology
    UndisclosedPhase 1

Regeneron Pharmaceuticals, Inc.

regeneron.com
17assets
  • FianlimabLAG3 / Monoclonal Antibody / Oncology
    1L metastatic melanoma, adjuvant melanomaPhase 3ActiveGlobal
  • CemiplimabLibtayo / PD-1 / Monoclonal Antibody / Oncology
    CancerPhase 2/3ActiveGlobal
  • DavutamigREGN5093 / METxMET / Bispecific Antibody / Oncology
    CancerPhase 2ActiveGlobal
  • ItepekimabIL-33 / Monoclonal Antibody / Immunology & Inflammation / Respiratory
    COPD, CRSwNPPhase 3ActiveGlobal
  • LinvoseltamabLynozyfic / BCMAxCD3 / Bispecific Antibody / Oncology
    Multiple myelomaPhase 2/3ActiveGlobal
  • MarlotamigREGN7075 / EGFRxCD28 / Bispecific Antibody / Oncology
    Solid TumorsPhase 2ActiveGlobal
  • OdronextamabOrdspono / CD20xCD3 / Bispecific Antibody / Oncology
    LymphomaPhase 2ActiveGlobal
  • UbamatamabREGN4018 / MUC16xCD3 / Bispecific Antibody / Oncology
    Ovarian CancerPhase 2ActiveGlobal
  • NezastomigREGN5678 / PSMAxCD28 / Bispecific Antibody / Oncology
    Prostate CancerPhase 2ActiveGlobal
  • RapirosiranALN-HSD / HSD17B13 / siRNA / Cardiovascular & Metabolic
    NASHPhase 2ActiveGlobal
  • ALN-ANG3ALN-ANG3 / ANGPTL3 / siRNA / Cardiovascular & Metabolic
    DyslipidemiaPhase 2ActiveGlobal
  • CemdisiranC5 / siRNA / Ophthalmology / Immunology
    Geographic atrophyClinicalActiveGlobal
  • PozelimabC5 / Monoclonal Antibody / Ophthalmology / Immunology
    Geographic atrophyClinicalActiveGlobal
  • BetV1REGN5713-5715 / BetV1 / Monoclonal Antibody / Immunology & Inflammation
    Birch AllergyClinicalActiveGlobal
  • DB-OTOOtarmeni / Otoferlin / Gene Therapy / Neurology / Hearing Loss
    Otoferlin-related hearing lossPhase 1/2ActiveGlobal
  • MibavademabUnknown / Biologic / Oncology
    CancerPhase 2ActiveGlobal
  • TrevogrumabREGN1033 / Myostatin / Monoclonal Antibody / Metabolic
    Muscle weakness/wastingPhase 2ActiveGlobal

Bristol Myers Squibb

bms.com
16assets
  • mezigdomidecereblon E3 ligase / CELMoD; oral targeted protein degrader / Hematology
    relapsed/refractory multiple myelomaPhase IIIactive
  • iberdomidecereblon E3 ligase / CELMoD; oral targeted protein degrader / Hematology
    multiple myelomaPhase IIIactive
  • golcadomidecereblon E3 ligase / CELMoD; oral targeted protein degrader / Hematology
    aggressive B-cell lymphomaPhase IIactive
  • pumitamigBNT327/BMS-986545 / PD-L1; VEGF-A / bispecific antibody / Oncology
    solid tumorsPhase IIIactive
  • iza-brenantibody-drug conjugate / Oncology
    solid tumorsPhase I/IIactive
  • nivolumabOPDIVO / PD-1 / monoclonal antibody / Oncology
    multiple oncology indicationsPhase IIIactive LCM
  • nivolumab and relatlimab HDPD-1; LAG-3 / antibody combination / Oncology
    oncology indicationsPhase IIIactive LCM
  • ipilimumabYERVOY / CTLA-4 / monoclonal antibody / Oncology
    multiple oncology indicationsPhase IIIactive LCM
  • KarXTCOBENFY / muscarinic receptors / small molecule / Neuroscience
    neuropsychiatric indicationsPhase IIIactive LCM
  • milvexianFactor XIa / small molecule anticoagulant / Cardiovascular
    thrombotic disordersPhase IIIactive
  • BMS-986278BMS-986278 / LPA1 / small molecule antagonist / Fibrosis
    idiopathic pulmonary fibrosisPhase IIIactive
  • BMS-986495BMS-986495 / MTBR tau / antibody / Neuroscience
    Alzheimer's diseasePhase IIactive
  • imzokitugCCR8 / monoclonal antibody / Oncology
    solid tumorsPhase I/IIactive
  • obexelimabCD19; FcγRIIb / bifunctional antibody / Immunology
    autoimmune diseasesPhase IIIactive
  • luspatercept-aamtREBLOZYL / TGF-beta superfamily ligands / recombinant fusion protein / Hematology
    anemia indicationsPhase IIIactive LCM
  • OncoACP3OncoACP3 / prostate cancer target / radiopharmaceutical therapeutic/diagnostic agent / Oncology
    prostate canceractive

Johnson & Johnson

investor.jnj.com
16assets
  • guselkumabTREMFYA / IL-23 / Monoclonal Antibody / Immunology
    PsoriasisPsoriatic ArthritisCrohn's Disease
  • ibrutinibIMBRUVICA / BTK / Small Molecule / Oncology
    Mantle Cell LymphomaOther B-cell malignancies
  • icotrokinraJNJ-2113 / IL-23R / Targeted Oral Peptide / Immunology
    PsoriasisPsoriatic Arthritis
  • JNJ-4804JNJ-4804 / Co-antibody / Co-antibody Therapy / Immunology
    Ulcerative Colitis
  • nipocalimabIMAAVY / FcRn / Monoclonal Antibody / Immunology / Neuroscience
    Generalized Myasthenia GravisRheumatoid ArthritisWarm Autoimmune Hemolytic Anemia
  • aticaprantKOR antagonist / Small Molecule / Neuroscience
    Adjunctive Treatment for Major Depressive Disorder with Anhedonia
  • RPGR Gene TherapyRPGR / Gene Therapy / Vision / Ophthalmology
    Retinitis Pigmentosa
  • teclistamabTECVAYLI / BCMA x CD3 / Bispecific Antibody / Oncology
    Multiple Myeloma
  • sCD59JNJ-1887 / sCD59 / Gene Therapy / Vision / Ophthalmology
    Geographic Atrophy
  • gemcitabine intravesical delivery systemTAR-200 / INLEXZO / DNA synthesis / Drug Delivery System / Oncology
    High Risk Non-Muscle Invasive Bladder Cancer
  • niraparib / abirateroneAKEEGA / PARP / CYP17 / Small Molecule Combination / Oncology
    Metastatic Castration-Sensitive Prostate CancerMetastatic Castration-Resistant Prostate Cancer
  • daratumumabDARZALEX / CD38 / Monoclonal Antibody / Oncology
    Multiple Myeloma
  • erdafitinibBALVERSA / FGFR / Small Molecule / Oncology
    Urothelial Carcinoma
  • apalutamideERLEADA / Androgen Receptor / Small Molecule / Oncology
    Prostate Cancer
  • ciltacabtagene autoleucelCARVYKTI / BCMA / CAR-T Cell Therapy / Oncology
    Multiple Myeloma
  • Filovirus multivalent vaccineVAC69120 / MVA-BN-Filo / Ebola Virus / Vaccine / Infectious Diseases
    Ebola

Zai Lab Limited

zailaboratory.com
16assets
  • NiraparibPARP / Inhibitor / Oncology
    Ovarian Cancer (1st line maintenance)ApprovedOvarian Cancer (Platinum sensitive relapsed maintenance)Approved
  • Tumor Treating FieldsOncology
    Glioblastoma (GBM)ApprovedPancreatic Cancer (1st line)Phase 3 / Pivotal
  • RipretinibTKI / Oncology
    Gastrointestinal Stromal Tumors (GIST) (4th line)Approved
  • RepotrectinibROS1 / TRK / Oncology
    ROS1+ NSCLCApprovedNTRK+ solid tumorsApproved
  • Tisotumab vedotinTF / ADC / Oncology
    Cervical Cancer (2nd line+ r/m)Phase 3 / PivotalCervical Cancer (1st line r/m, combo)Phase 2 / POC
  • Zocilurtatug pelitecanZL-1310 / Zoci / DLL3 / ADC / Oncology
    ES-SCLCPhase 3 / PivotalOther NECsPhase 2 / POC
  • ZL-6201LRRC15 / ADC / Oncology
    Sarcoma & CAF+ Solid TumorPhase 1
  • ZL-1311MUC17xCD3 / Oncology
    GI TumorsPre-clinical
  • ZL-1222PD-1/IL-12 / Oncology
    Solid TumorsPre-clinical
  • EfgartigimodFcRn / Immunology
    Generalized Myasthenia Gravis (gMG)ApprovedChronic Inflammatory Demyelinating Polyneuropathy (CIDP)ApprovedMyositisPhase 3 / Pivotal
  • PovetaciceptBAFF/APRIL / Immunology
    IgA NephropathyPhase 3 / PivotalPrimary Membranous NephropathyPhase 2 / POC
  • ElegrobartIGF-1R / Immunology
    TEDPhase 3 / Pivotal
  • ZL-1503IL13/IL31R / Immunology
    Mod-to-Sev ADPhase 1
  • Xanomeline-TrospiumKarXT / Neuroscience
    SchizophreniaApproved
  • OmadacyclineInfectious Disease
    Acute Bacterial Skin and Skin Structure Infection (ABSSSI)ApprovedCommunity-Acquired Bacterial Pneumonia (CABP)Approved
  • Sulbactam-DurlobactamInfectious Disease
    HABP/VABP caused by Susceptible Isolates of Acinetobacter Baumannii-calcoaceticus ComplexApproved

Takeda Pharmaceutical Company Limited

takeda.com
15assets

Agenus Inc.

agenusbio.com
14assets
  • BotensilimabAGEN1181 / Anti-CTLA-4 / Fc-enhanced anti-CTLA-4 antibody / Oncology
    Non-MSI-H 4L+ metastatic colorectal cancerPhase 3Sites activeNon-MSI-H metastatic colorectal cancer NLMPhase 2Enrollment completePD-1 R/R melanomaPhase 2
  • BalstilimabAGEN2034 / Anti-PD-1 / PD-1 inhibitor antibody / Oncology
    MSS metastatic colorectal cancer in combination with botensilimabPhase 3Sites activePD-1 R/R melanoma in combination with botensilimabPhase 2
  • AGEN2373AGEN2373 / CD137 / CD137 agonist antibody / Oncology
    Solid tumorsPhase 1PD-1 R/R melanoma with botensilimabPhase 2
  • AGEN1571AGEN1571 / Anti-ILT-2 / Antibody / Oncology
    Solid tumorsPhase 1
  • AGEN1777AGEN1777 / Anti-TIGIT x CD96 / Bispecific antibody / Oncology
    Solid tumors with balstilimabPhase 1
  • AGEN1423AGEN1423 / Anti-CD73 x TGFB / Bispecific antibody / Oncology
    Solid tumorsPhase 1
  • INCAGN1876INCAGN1876 / Anti-GITR / Antibody / Oncology
    Solid tumorsPhase 1
  • AGEN1949AGEN1949 / OX40 / OX40 agonist antibody / Oncology
    Solid tumorsPhase 1
  • MK-4830MK-4830 / ILT4 / Anti-ILT4 antagonist antibody / Oncology
    Neoadjuvant ovarian cancerPhase 2Ongoing
  • INCAGN2390INCAGN2390 / TIM-3 / Anti-TIM-3 antagonist antibody / Oncology
    Melanoma and SCCHN in combinationIn development
  • INCAGN2385INCAGN2385 / LAG-3 / Anti-LAG-3 antagonist antibody / Oncology
    Melanoma and SCCHN in combinationIn development
  • CR6086 + BalstilimabCR6086; AGEN2034 / EP4 + PD-1 / EP4 antagonist plus PD-1 antagonist / Oncology
    pMMR-MSS colorectal cancerPhase 1/2Ongoing
  • NLM001 + ZalifrelimabNLM-001 / Hedgehog + CTLA-4 / Hedgehog inhibitor plus CTLA-4 antagonist / Oncology
    Advanced pancreatic cancerPhase 1/2Ongoing
  • OBT076 + BalstilimabOBT076; AGEN2034 / CD205 + PD-1 / Antibody-drug conjugate plus PD-1 antibody / Oncology
    Solid tumorsOngoing

Alvotech

alvotech.com
14assets
  • High-concentration, low-volume adalimumabAVT02 / HUMIRA® / Biosimilar / Immunology
    Biosimilar to HUMIRA®ApprovedApprovedU.S.Europe (EEA, UK, Switzerland, Balkans)CanadaAustraliaSaudi ArabiaIsraelEgyptSouth AfricaMoroccoPeruBolivia
  • ustekinumabAVT04 / STELARA® / Biosimilar / Immunology
    Biosimilar to STELARA®ApprovedApprovedU.S.JapanCanadaEU/EEA
  • denosumabAVT03 / PROLIA®/XGEVA® / Biosimilar / Bone Disease
    Biosimilar to PROLIA®/XGEVA®ApprovedApprovedJapanEU/EEA
  • golimumabAVT05 / SIMPONI®/SIMPONI ARIA® / Biosimilar / Immunology
    Biosimilar to SIMPONI®/SIMPONI ARIA®ApprovedApprovedJapanEU/EEAUnited Kingdom
  • afliberceptAVT06 / EYLEA® / Biosimilar / Ophthalmology
    Biosimilar to EYLEA®ApprovedApprovedEU/EEAJapanUnited Kingdom
  • omalizumabAVT23 / XOLAIR® / Biosimilar / Respiratory
  • vedolizumabAVT16 / ENTYVIO® / Biosimilar / Immunology
  • pembrolizumabAVT33 / KEYTRUDA® / Biosimilar / Oncology
  • certolizumab pegolAVT10 / CIMZIA® / Biosimilar / Immunology
  • ixekizumabAVT28 / TALTZ® / Biosimilar / Immunology
  • canakinumabAVT48 / ILARIS® / Biosimilar / Immunology
  • guselkumabAVT41 / TREMFYA® / Biosimilar / Immunology
  • ofatumumabAVT65 / KESIMPTA® / Biosimilar / Immunology
  • dupilumabAVT19 / DUPIXENT® / Biosimilar / Immunology

Telix Pharmaceuticals Limited

telixpharma.com
14assets
  • 177Lu rosopatamab tetraxetanTLX591-Tx / PSMA / Antibody / Urologic Oncology
    Prostate Cancer
  • 177Lu-DOTA-PSMATLX597-Tx / PSMA / Small molecule / Urologic Oncology
    Prostate Cancer
  • 177Lu-girentuximabTLX250-Tx / CAIX / Antibody / Urologic Oncology
    Kidney Cancer / ccRCC
  • 131I-IPATLX101-Tx / LAT / Small molecule / Neuro-oncology
    Brain Cancer / Glioma
  • 90Y-besilesomabTLX66-Tx / CD66 / Antibody / Hematology
    Bone-marrow conditioning
  • 225Ac-RADmAbTLX592-Tx / PSMA / Antibody / Urologic Oncology
    Prostate Cancer
  • 225Ac-girentuximabTLX252-Tx / CAIX / Antibody / Urologic Oncology
    Kidney Cancer
  • UndisclosedTLX400-Tx / FAP / Small molecule / Urologic Oncology
    Bladder Cancer
  • 211At-APATLX102-Tx / LAT / Small molecule / Neuro-oncology
    Brain Cancer
  • -olaratumab conjugateTLX300-Tx / PDGFRα / Antibody / Musculoskeletal Oncology
    Soft Tissue Sarcoma
  • 153Sm-DOTMPTLX090-Tx / Small molecule / Musculoskeletal Oncology
    Bone metastasesPain palliation
  • 68Ga-PSMA-11TLX591-CDx / Illuccix / Gozellix / PSMA / Diagnostic Radiopharmaceutical / Oncology
    Prostate Cancer Imaging
  • 18F-floretyrosineTLX101-CDx / Pixclara / Pixlumi / LAT / Diagnostic Radiopharmaceutical / Neuro-oncology
    Glioma Imaging
  • 89Zr-DFO-girentuximabTLX250-CDx / Zircaix / CAIX / Diagnostic Radiopharmaceutical / Oncology
    Clear Cell Renal Cell Carcinoma (ccRCC) Imaging

Lantheus Holdings, Inc.

lantheus.com
13assets

Argenx SE

argenx.com
12assets
  • EfgartigimodVYVGART; VYVGART Hytrulo / FcRn / antibody fragment / Autoimmune
    Generalized Myasthenia Gravis (gMG)CommercialChronic Inflammatory Demyelinating Polyneuropathy (CIDP)CommercialPrimary Immune Thrombocytopenia (ITP)CommercialJapan
  • EmpasiprubartC2 / monoclonal antibody / Autoimmune
    Multifocal Motor Neuropathy (MMN)RegistrationalDelayed Graft Function (DGF)Proof of ConceptChronic Inflammatory Demyelinating Polyneuropathy (CIDP)Registrational
  • AdimanebartMuSK / agonist antibody / Neurology
    Congenital Myasthenic Syndromes (CMS)Proof of ConceptSpinal Muscular Atrophy (SMA)Proof of Concept
  • ARGX-109ARGX-109 / IL-6 / antibody / Undisclosed
    UndisclosedPhase 1
  • ARGX-121ARGX-121 / IgA / antibody / Undisclosed
    UndisclosedPhase 1
  • ARGX-213ARGX-213 / FcRn / antibody / Undisclosed
    UndisclosedPhase 1
  • ARGX-118ARGX-118 / Galectin-10 / Airway Inflammation
    Airway InflammationPreclinical
  • ARGX-125ARGX-125 / bispecific antibody / Undisclosed
    UndisclosedPreclinical
  • TSP-101TSP-101 / Fn14 / Undisclosed
    UndisclosedPreclinical
  • LP0145ARGX-112 / IL-22R / SIMPLE Antibody / Dermatology
    Atopic Dermatitispartnered
  • AGMB-101ARGX-114 / MET / HGF-mimetic agonist antibody
  • ABBV-151ARGX-115 / GARP-TGF-beta1 / SIMPLE Antibody / Oncology
    Tumorspartnered

Arcus Biosciences, Inc.

arcusbio.com
12assets

Biohaven Ltd.

biohaven.com
11assets
  • Taldefgrobep AlfaBHV-2000 / myostatin/activin receptor signaling / recombinant protein; myostatin-activin pathway inhibitor / neuromuscular; metabolic
    Spinal muscular atrophyPhase 3ObesityPhase 1
  • OpakalimBHV-7000 / Kv7.2/Kv7.3 potassium channels / small molecule Kv7 activator / neurology; psychiatry
    Focal epilepsyPhase 3Generalized epilepsyPhase 3Major depressive disorderPhase 2
  • TRPM3 AntagonistBHV-2100 / TRPM3 / oral small molecule antagonist / pain
    Pain disordersPhase 2
  • TYK2/JAK1 InhibitorBHV-8000 / TYK2/JAK1 / brain-penetrant small molecule inhibitor / neuroinflammation
    Parkinson's diseasePhase 3Prevention of amyloid therapy induced ARIAPhase 1Alzheimer's diseasePhase 1
  • IgG DegraderBHV-1300 / IgG / MoDE extracellular protein degrader / immunology
    Graves' disease / rheumatoid arthritisPhase 1
  • IgG DegraderBHV-1310 / IgG / MoDE extracellular protein degrader / immunology
    Myasthenia gravisPreclinical
  • Gd-IgA1 TRAP DegraderBHV-1400 / galactose-deficient IgA1 / TRAP extracellular protein degrader / immunology; renal
    IgA nephropathyPhase 1
  • β1AR Autoantibody DegraderBHV-1600 / β1AR autoantibodies / bifunctional MoDE degrader / cardiovascular
    Peripartum cardiomyopathyPhase 1
  • Trop2 ADC +/- PD1BHV-1510 / TROP2 / antibody-drug conjugate / oncology
    Advanced or metastatic epithelial tumorsPhase 1
  • FGFR3 ADCBHV-1530 / FGFR3 / antibody-drug conjugate / oncology
    Urothelial cancer and other tumorsPhase 1
  • CD30 ADCBHV-1500 / CD30 / antibody-drug conjugate / oncology
    Hodgkin lymphomaPreclinical

Biogen Inc.

biogen.com
11assets
  • LecanemabLEQEMBI / Aβ / mAb / Neurology
    Preclinical Alzheimer's diseasePhase 3Early Alzheimer's disease, SC-AI initiationRegulatory review; FDA PDUFA May 24, 2026U.S.
  • DiranersenBIIB080 / tau / ASO / Neurology
    Early Alzheimer's diseasePhase 2PoC readout reported May 14, 2026
  • BIIB091BIIB091 / BTK / peripheral BTK inhibitor / Neurology
    Multiple sclerosisPhase 2
  • Dapirolizumab pegolCD40L / pegylated antibody fragment / Immunology
    Systemic lupus erythematosusPhase 3
  • LitifilimabBDCA2 / mAb / Immunology
    Systemic lupus erythematosusPhase 3Cutaneous lupus erythematosusPhase 3FDA Breakthrough Therapy DesignationU.S.
  • BIIB142BIIB142 / IRAK4 / degrader / Immunology
    Autoimmune diseasePhase 1
  • FelzartamabCD38 / mAb / Rare disease
    Antibody-mediated rejectionPhase 3IgA nephropathyPhase 3Primary membranous nephropathyPhase 3
  • OmaveloxoloneSKYCLARYS / Nrf2 / activator / Rare disease
    Pediatric Friedreich ataxiaPhase 3
  • SalanersenBIIB115 / SMN / ASO / Rare disease
    Spinal muscular atrophyPhase 3
  • ZorevunersenSCN1A / ASO / Rare disease
    Dravet syndromePhase 3
  • Nusinersen high doseSPINRAZA / SMN2 / splice modulator / Rare disease
    Spinal muscular atrophyApproved in U.S.; under review in E.U.U.S.E.U.

Denali Therapeutics Inc.

denalitherapeutics.com
11assets
  • tividenofusp alfa-eknmDNL310; ETV:IDS / AVLAYAH / IDS enzyme replacement; TfR TransportVehicle-enabled delivery / Enzyme TransportVehicle biologic / Lysosomal storage disorders
    Hunter syndrome (MPS II)Approved; Phase 2/3 confirmatory study ongoingU.S. accelerated approval; global Phase 2/3 COMPASS ongoingUSGlobal
  • DNL126ETV:SGSH / SGSH enzyme replacement / Enzyme TransportVehicle biologic / Lysosomal storage disorders
    Sanfilippo syndrome Type A (MPS IIIA)Phase 1/2; Phase 3 plannedOngoing Phase 1/2; global Phase 3 confirmatory study plannedGlobal
  • DNL593TAK-594/DNL593; PTV:PGRN / Progranulin replacement / Protein TransportVehicle biologic / Neurodegenerative disease
    GRN-related frontotemporal dementia (FTD-GRN)Phase 1/2Ongoing; Denali received notice that Takeda will terminate collaboration, with Denali planning to continue developmentGlobal
  • DNL628OTV:MAPT / MAPT / tau / Oligonucleotide TransportVehicle therapeutic / Neurodegenerative disease
    Alzheimer's diseasePhase 1bCTA approved; study start-up underway
  • DNL952ETV:GAA / GAA enzyme replacement / Enzyme TransportVehicle biologic / Lysosomal storage disorders
    Pompe diseasePhase 1IND clinical hold lifted; proceeding to Phase 1US
  • BIIB122/DNL151DNL151; BIIB122 / LRRK2 / Small molecule inhibitor / Neurodegenerative disease
    Parkinson's diseasePhase 2bLUMA enrollment completed; readout expected 2026GlobalLRRK2-associated Parkinson's diseasePhase 2aBEACON ongoing
  • eclitasertibSAR443122/DNL758 / RIPK1 / Small molecule inhibitor / Inflammatory disease
    Ulcerative colitisPhase 2Developed by Sanofi; Phase 2 results expected in 1H 2026
  • DNL921ATV:Abeta / Amyloid beta / Antibody TransportVehicle therapeutic / Neurodegenerative disease
    Alzheimer's diseaseIND-enablingPhase 1/1b initiation planned
  • DNL111ETV:GCase / GCase / Enzyme TransportVehicle biologic / Neurodegenerative disease; lysosomal storage disorders
    Parkinson's diseaseIND-enablingIND-enablingGaucher diseaseIND-enablingIND-enabling
  • DNL622ETV:IDUA / IDUA enzyme replacement / Enzyme TransportVehicle biologic / Lysosomal storage disorders
    MPS IIND-enablingIND-enabling
  • DNL422OTV:SNCA / SNCA / alpha-synuclein / Oligonucleotide TransportVehicle therapeutic / Neurodegenerative disease
    Parkinson's diseaseIND-enablingIND-enabling

Incyte Corporation

incyte.com
11assets
  • INCA033989INCA033989 / mutCALR / Hematology
    CALR-mutated essential thrombocythemia (2L)Phase 3Initiation mid-2026USCALR-mutated myelofibrosis (1L)Phase 1Data expected 2H 2026CALR-mutated myelofibrosis (2L)Phase 3Initiation 2H 2026
  • INCB161734INCB161734 / KRAS G12D / Oncology
    1L G12D-mutated pancreatic ductal adenocarcinoma (PDAC)Phase 3Ongoing (in combo with SOC chemo)KRAS G12D-mutated solid tumorsPhase 1Data expected 2H 2026
  • INCA33890INCA33890 / TGFβR2 × PD-1 / bispecific / Oncology
    1L microsatellite-stable colorectal cancer (MSS CRC)Phase 3Ongoing1L MSS PDAC (combo with SOC)Phase 1Data expected 2H 2026
  • INCB123667INCB123667 / CDK2 / Oncology
    Platinum-resistant ovarian cancer (PROC)PivotalOngoing1L maintenance ovarian cancer (CCNE1+)Phase 3Initiation planned 2H 2026
  • povorcitinibJAK1 / small molecule / Inflammation and Autoimmunity
    Moderate-to-severe hidradenitis suppurativa (HS)Phase 3NDA accepted; approval anticipated 1Q 2027 (US), late 2026 (EU)USEUNonsegmental vitiligoPhase 3Positive data; sNDA submission 1H 2027Moderate-to-severe prurigo nodularis (PN)Phase 3Ongoing; topline data 4Q 2026
  • ruxolitinib creamOpzelura / JAK1/JAK2 / topical / Inflammation and Autoimmunity
    Moderate atopic dermatitisApprovedApproval and launch (ex-US)EUMild-to-moderate hidradenitis suppurativa (HS)Phase 3Ongoing; topline data 4Q 2026
  • axatilimabNiktimvo / CSF-1R / Hematology
    1L chronic GVHD (+ ruxolitinib)PivotalData 2H 20261L chronic GVHD (+ steroids)Data early 20283L+ chronic GVHDApprovedApprovedUS
  • INCB160058INCB160058 / JAK2V617F / Hematology
    JAK2 V617F-mutated myeloproliferative neoplasms (MPNs)Phase 1Data 2H 2026 (ASD formulation)
  • tafasitamabMonjuvi / CD19 / Hematology
    1L diffuse large B-cell lymphoma (DLBCL)Phase 3sBLA submission 1H 2026USRelapsed/refractory DLBCLApprovedApprovedUSEUJapan
  • ruxolitinib XRJakafi XR / JAK1/JAK2 / Hematology
    Myelofibrosis, polycythemia vera, chronic GVHDRegistrationFDA resubmissionUS
  • retifanlimabZynyz / PD-1 / Oncology
    Squamous cell carcinoma of the anal canal (SCAC)ApprovedApproved (EC approval noted)USEUMerkel cell carcinomaApprovedApprovedUSEUJapan

Krystal Biotech, Inc.

krystalbio.com
11assets
  • B-VECB-VEC / VYJUVEK / Type VII collagen (COL7A1) / Gene Therapy (HSV-1 vector) / Dermatology
    Dystrophic Epidermolysis Bullosa (DEB)CommercialApprovedGlobal
  • KB105KB105 / Transglutaminase 1 (TGM1) / Gene Therapy / Dermatology
    TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)Phase 1/2ActiveGlobal
  • KB104KB104 / Serine Peptidase Inhibitor Kazal Type 5 (SPINK5) / Gene Therapy / Dermatology
    Netherton SyndromePreclinicalActiveGlobal
  • KB407KB407 / Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) / Gene Therapy / Respiratory
    Cystic FibrosisPhase 1ActiveGlobal
  • KB408KB408 / Alpha-1 antitrypsin / Gene Therapy / Respiratory
    Alpha-1 Antitrypsin Deficiency (AATD)PreclinicalActiveGlobal
  • KB707KB707 / IL-12 and IL-2 / Gene Therapy (HSV-1 vector) / Oncology
    Locally advanced or metastatic solid tumor malignanciesPhase 1ActiveGlobal
  • KB301KB301 / Type III collagen / Gene Therapy / Aesthetics
    Aesthetic Skin ConditionsPhase 1/2ActiveGlobal
  • KB302KB302 / Type I collagen / Gene Therapy / Aesthetics
    Aesthetic Skin ConditionsPreclinicalActiveGlobal
  • KB303KB303 / Elastin / Gene Therapy / Aesthetics
    Aesthetic Skin ConditionsPreclinicalActiveGlobal
  • KB304KB304 / Type III collagen and Elastin / Gene Therapy / Aesthetics
    Aesthetic Skin ConditionsPreclinicalActiveGlobal
  • KB305KB305 / Type IV collagen / Gene Therapy / Aesthetics
    Aesthetic Skin ConditionsPreclinicalActiveGlobal

Sanofi

sanofi.com
11assets
  • amlitelimabOX40L / Monoclonal antibody / Immunology
    Atopic dermatitisPhase 3ActiveGlobal
  • tolebrutinibBTK / Small molecule / Neurology
    Multiple sclerosisRegistrationActiveGlobalUS
  • lunsekimigBiologic / Immunology and Inflammation
    Asthma / Respiratory diseasesPhase 2ActiveGlobal
  • rilzabrutinibBTK / Small molecule / Rare Blood Disorders / Immunology
    Sickle cell diseasePhase 2/3ActiveGlobalIgG4-related diseasePhase 3ActiveGlobalAsthmaPhase 2ActiveGlobal
  • venglustatSmall molecule / Rare Diseases
    Gaucher disease type 3 (GD3)Phase 3ActiveGlobal
  • frexalimabCD40L / Monoclonal antibody / Immunology
    Multiple sclerosisPhase 3ActiveGlobal
  • SAR441566SAR441566 / TNFR1si / Small molecule / Immunology
    Immunological diseasesPhase 2ActiveGlobal
  • duvakitugTL1A / Monoclonal antibody / Immunology
    Ulcerative colitisPhase 2ActiveGlobalCrohn's diseasePhase 2ActiveGlobal
  • itepekimabIL-33 / Monoclonal antibody / Immunology and Inflammation
    COPDPhase 3ActiveGlobal
  • isatuximabSarclisa / CD38 / Monoclonal antibody / Oncology
    Multiple myeloma (subcutaneous)RegistrationActiveEU
  • acoziboroleSmall molecule / Infectious Diseases
    Sleeping sicknessRegistrationActiveAfricaEU

BioAtla, Inc.

bioatla.com
10assets
  • Ozuriftamab vedotinBA3021 / ROR2 / CAB-ROR2-ADC / Oncology
    OPSCCPhase 3
  • Mecbotamab vedotinBA3011 / AXL / CAB-AXL-ADC / Oncology
    Sarcoma (soft tissue and bone)Phase 2mKRAS NSCLCPhase 2
  • EvalstotugBA3071 / CTLA-4 / CAB-CTLA-4 antibody / Oncology
    Unresectable and/or metastatic cutaneous melanomaPhase 2
  • BA3182BA3182 / EpCAM x CD3 / Dual CAB T cell engager / Oncology
    AdenocarcinomaPhase 1ongoing
  • BA3361BA3361 / Nectin-4 / CAB-Nectin4-ADC / Oncology
    Multiple tumor typesPreclinicalIND-approved
  • BA3151BA3151 / B7-H4 / CAB-B7H4-ADC / Oncology
    Breast cancerPreclinical
  • BA3142BA3142 / B7-H3 x CD3 / Dual CAB TCE / Oncology
    Multiple tumor typesPreclinicalIND-ready
  • BA3311BA3311 / EGFR x CD3 / TCE / Oncology
    Multiple tumor typesPreclinical
  • BA3241BA3241 / Trop2 x CD3 / Dual CAB TCE / Oncology
    Epidermoid cancerPreclinical
  • BA3362BA3362 / Nectin4 x CD3 / Dual CAB TCE / Oncology

Corcept Therapeutics Incorporated

corcept.com
10assets
  • Relacorilantglucocorticoid receptor / selective cortisol modulator / Endocrinology
    Hypercortisolism (GRACE)Phase IIIFiledHypercortisolism associated with adrenal adenoma or hyperplasia (GRADIENT)Phase IIIFiledLong-term safety extensionPhase IIFiled
  • KorlymKorlym / glucocorticoid receptor / cortisol modulator / Endocrinology
    Prevalence and treatment of hypercortisolism in difficult-to-control type 2 diabetes (CATALYST)Phase IV
  • LifyorliLifyorli / glucocorticoid receptor / selective cortisol modulator / Oncology
    Platinum-resistant ovarian cancer (ROSELLA)Phase IIIApproved
  • Relacorilant + Nab-paclitaxel + Bevacizumabglucocorticoid receptor / selective cortisol modulator combination / Oncology
    Platinum-resistant ovarian cancer (BELLA Arm A)Phase IIPlatinum-sensitive ovarian cancer (BELLA Arm B)Phase III
  • Relacorilant + Nab-paclitaxelglucocorticoid receptor / selective cortisol modulator combination / Oncology
    Endometrial cancer (BELLA Arm C)Phase IICervical cancer (STELLA)Phase II
  • Relacorilant + Nab-paclitaxel + Gemcitabineglucocorticoid receptor / selective cortisol modulator combination / Oncology
    Pancreatic cancer (TRIDENT)Phase II
  • Nenocorilant + Nivolumabglucocorticoid receptor / selective cortisol modulator combination / Oncology
    Solid tumors (SYNERGY)Phase II
  • Relacorilant + Enzalutamideglucocorticoid receptor / selective cortisol modulator combination / Oncology
    Prostate cancerPhase II
  • Dazucorilantglucocorticoid receptor / selective cortisol modulator / Neurology
    ALS (DAZALS)Phase II
  • Miricorilantglucocorticoid receptor / selective cortisol modulator / Metabolism
    MASH (MONARCH)Phase II

HUTCHMED (China) Limited

hutch-med.com
10assets
  • FruquintinibHMPL-013 / ELUNATE / FRUZAQLA / VEGFR 1/2/3 / Small molecule / Oncology
    Colorectal cancerApproved/MarketedApprovedChinaUSEuropeJapanGastric cancerPhase IIIActiveGlobalOther solid tumors (combination studies)ClinicalActiveGlobal
  • SavolitinibHMPL-504 / AZD6094 / ORPATHYS / c-MET / Small molecule / Oncology
    Non-small cell lung cancer (MET exon 14)Approved/MarketedApprovedChinaNSCLC combinations (with immunotherapy/targeted therapy)Phase IIIActiveGlobal
  • SurufatinibHMPL-012 / SULANDA / VEGFR/FGFR/CSF-1R / Small molecule / Oncology
    Neuroendocrine tumorsApproved/MarketedApprovedChina
  • SovleplenibHMPL-523 / Syk / Small molecule / Hematology/Immunology
    Immune thrombocytopenia (ITP)NDA/Regulatory reviewUnder regulatory reviewChina
  • FanregratinibHMPL-453 / FGFR / Small molecule / Oncology
    Cholangiocarcinoma (FGFR2 fusion)NDA/Regulatory reviewUnder regulatory reviewChina
  • HMPL-760HMPL-760 / BTK (non-covalent) / Small molecule / Oncology/Hematology
    Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)Phase IIIInitiatedChina
  • HMPL-A251HMPL-A251 / HER2 (PI3K/PIKK payload) / Antibody-Targeted Therapy Conjugate (ATTC) / Oncology
    HER2-positive/HER2-low solid tumorsPhase IActiveChinaUS
  • HMPL-A580HMPL-A580 / EGFR (PI3K/PIKK payload) / Antibody-Targeted Therapy Conjugate (ATTC) / Oncology
    Solid tumorsPhase IInitiatedGlobal
  • HMPL-A830HMPL-A830 / ATTC (undisclosed) / Antibody-Targeted Therapy Conjugate (ATTC) / Oncology
    Solid tumorsPreclinical/Phase I plannedPlannedGlobal
  • TazemetostatTAZVERIK / EZH2 / Small molecule / Oncology
    Epithelioid sarcoma / follicular lymphomaLicensed/CommercialLicensed product updateChina

Eli Lilly and Company

lilly.com
10assets

Pfizer, Inc.

pfizer.com
10assets
  • BerobenatidePF-06954522 / GLP-1/GIP / Small Molecule / Internal Medicine
    Chronic Weight ManagementPhase 2bOngoingGlobal
  • elranatamabPF-06863135 / ELREXFIO / BCMA x CD3 / Bispecific Antibody / Oncology
    Double-class Exposed Relapsed / Refractory Multiple MyelomaPhase 3OngoingGlobal
  • ritlecitinibPF-06651600 / LITFULO / JAK3/TEC / Small Molecule / Inflammation and Immunology
    VitiligoPhase 3OngoingGlobalModerate Alopecia AreataPhase 3OngoingGlobal
  • marstacimabPF-06741086 / HYMPAVZI / TFPI / Monoclonal Antibody / Rare Disease
    Hemophilia A/B with InhibitorsRegistrationOngoingGlobal
  • MevrometostatPF-06821497 / EZH2 / Small Molecule / Oncology
    1-2L Metastatic Castration-resistant Prostate Cancer Post-abirateronePhase 3OngoingGlobal
  • Sigvotatug vedotinPF-08046047 / Integrin beta-6 / Antibody-Drug Conjugate (ADC) / Oncology
    Non-Small Cell Lung Cancer (NSCLC)Phase 3OngoingGlobal
  • VepdegestrantARV-471 / Estrogen Receptor (ER) / PROTAC Protein Degrader / Oncology
    ER+/HER2- Metastatic Breast CancerPhase 3OngoingGlobal
  • PCV25PF-07872412 / Pneumococcus / Vaccine / Vaccines
    Pneumococcal InfectionPhase 3OngoingGlobal
  • enfortumab vedotinPADCEV / Nectin-4 / Antibody-Drug Conjugate (ADC) / Oncology
    Muscle-invasive Bladder Cancer (Bladder Sparing)Phase 3OngoingGlobal
  • Lyme Disease Vaccine CandidatePF-07307405 / Borrelia burgdorferi OspA / Vaccine / Vaccines
    Lyme Disease InfectionPhase 3OngoingGlobal

Adagene Inc.

adagene.com
9assets
  • ADG126ADG126 / muzastotug / CTLA-4 / fully human anti-CTLA-4 SAFEbody / Oncology
    advanced/metastatic solid tumorsPhase 1b/2dose expansion ongoing in combination with anti-PD-1 therapies
  • ADG116ADG116 / CTLA-4 / fully human anti-CTLA-4 NEObody / Oncology
    advanced/metastatic solid tumorsPhase 1b/2ongoing
  • ADG206ADG206 / CD137 / masked IgG1 Fc-engineered anti-CD137 POWERbody / Oncology
    advanced/metastatic tumorsPhase 1ongoing
  • ADG106ADG106 / CD137 / fully human ligand-blocking agonistic anti-CD137 IgG4 mAb NEObody / Oncology
    advanced/metastatic solid tumors and/or relapsed/refractory non-Hodgkin's lymphomaPhase 1b/2ongoing
  • ADG153ADG153 / CD47 / masked anti-CD47 IgG1 SAFEbody / Oncology
    hematologic and solid tumorsIND-enablingpreclinical
  • ADG138ADG138 / HER2 x CD3 / HER2xCD3 POWERbody T-cell engager / Oncology
    HER2-expressing solid tumorsIND-enablingpreclinical
  • ADG152ADG152 / CD20 x CD3 / bispecific CD20xCD3 T-cell engager POWERbody / Oncology
    B-cell malignanciesIND-enablingpreclinical
  • ADG104ADG104 / PD-L1 / antibody / Oncology
    cancerPhase 2in development by Sanjin
  • ADG125ADG125 / CSF-1R / antibody / Oncology
    cancerPhase 1in development by Dragon Boat Biopharmaceutical

CRISPR Therapeutics AG -

ir.crisprtx.com
9assets
  • CASGEVYexa-cel / CASGEVY / BCL11A erythroid-specific enhancer / Non-viral ex vivo CRISPR/Cas9 gene-edited autologous cell therapy / Hemoglobinopathies
    Sickle cell disease, ages 5-11Regulatory submissions expected H1 2026Active pediatric expansionGlobalTransfusion-dependent beta thalassemia, ages 5-11Regulatory submissions expected H1 2026Active pediatric expansionGlobal
  • CTX310CTX310 / ANGPTL3 / In vivo CRISPR/Cas9 gene editing; LNP delivery / Cardiovascular/metabolic
    Severe hypertriglyceridemiaPhase 1bActive; update expected H2 2026Refractory hypercholesterolemiaPhase 1bActive; update expected H2 2026Heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, mixed dyslipidemias or severe hypertriglyceridemiaPhase 1Developed/being evaluated
  • CTX320CTX320 / LPA / In vivo CRISPR/Cas9 gene editing; LNP delivery / Cardiovascular
    Elevated lipoprotein(a)Clinical trial / dose escalationActive; Lp(a) program update expected in 2026
  • CTX321CTX321 / LPA / Next-generation in vivo CRISPR/Cas9 gene editing; LNP delivery / Cardiovascular
    Elevated lipoprotein(a)IND/CTA-enablingActive
  • CTX460CTX460 / SERPINA1 / In vivo SyNTase gene correction; LNP delivery / Rare disease
    Alpha-1 antitrypsin deficiencyPreclinical; clinical trial expected mid-2026Active
  • CTX340CTX340 / AGT / In vivo CRISPR/Cas9 gene editing; LNP delivery / Cardiovascular
    Refractory hypertensionIND/CTA-enabling; clinical trial expected H1 2026Active
  • CTX611SRSD107 / Factor XI / FXI mRNA / Long-acting double-stranded siRNA / Thromboembolic/cardiovascular diseases
    Venous thromboembolism prevention after total knee arthroplastyPhase 2Ongoing; top-line data expected H2 2026EuropeAtrial fibrillation, venous thromboembolism, ischemic stroke, cancer-associated thrombosis, chronic kidney disease, peripheral vascular disease, chronic coronary artery diseaseTarget indications disclosed
  • Zugocabtagene geleucelzugo-cel; formerly CTX112 / CD19 / Allogeneic CAR-T cell therapy; CRISPR Cas9 engineered / Autoimmune disease; oncology
    Systemic lupus erythematosusPhase 1Ongoing; update expected H2 2026Systemic sclerosisPhase 1Ongoing; update expected H2 2026Inflammatory myositisPhase 1Ongoing; update expected H2 2026
  • CTX213CTX213 / iPSC-derived allogeneic gene-edited beta islet cell precursor therapy / Regenerative medicine / diabetes
    Type 1 diabetesPreclinical; progressing toward clinicActive

Evotec SE

evotec.com
9assets
  • EVT8683BMS-986419 / eIF2b / Neuroscience
    Neurodegeneration
  • CNTX 6016CB2 / Pain
    Pain
  • EVT801VEGFR3 / Oncology
    Oncology
  • EVT401P2X7 / Immunology
    InflammationAutoimmune
  • EVT894Infectious Diseases
    Chikungunya
  • EXS21546A2a / Oncology
    Oncology
  • DSP-11815-HT1A / Neuroscience
    Obsessive Compulsive Disorder (OCD)
  • CT7001CDK7 / Oncology
    Oncology
  • TPM203Immunology
    Pemphigus Vulgaris

Ideaya Biosciences, Inc.

ideayabio.com
9assets
  • DarovasertibIDE196 / PKC / Small Molecule / Oncology
    1L metastatic uveal melanoma (HLA-A*02:01 negative)Phase 2/3Positive topline; NDA initiationGlobalNeoadjuvant primary uveal melanomaPhase 2/3OngoingUS
  • IDE397IDE397 / MAT2A / Small Molecule / Oncology
    MTAP-deleted solid tumorsPhase 1OngoingUS
  • IDE849IDE849 / DLL3 / ADC / Oncology
    DLL3-expressing solid tumors (SCLC, NEC)Phase 1OngoingUS
  • IDE161IDE161 / PARG / Small Molecule / Oncology
    HRD solid tumorsPhase 1RecruitingUS
  • IDE034IDE034 / PTK7/B7H3 / Bispecific ADC / Oncology
    B7H3/PTK7 solid tumors (NSCLC, CRC, breast, ovarian)Phase 1OngoingUS
  • IDE892IDE892 / PRMT5 / Small Molecule / Oncology
    MTAP-deleted solid tumorsPhase 1OngoingUS
  • IDE574IDE574 / KAT6/7 / Small Molecule / Oncology
    Solid tumors (breast, prostate, CRC, lung)Phase 1OngoingUS
  • IDE275IDE275 / Werner Helicase (WRN) / Small Molecule / Oncology
    MSI-high solid tumorsPhase 1OngoingUS
  • IDE705IDE705 / Pol Theta (POLQ) / Small Molecule / Oncology
    HRD solid tumorsPhase 1OngoingUS

Insmed Incorporated

insmed.com
9assets
  • BrensocatibBRINSUPRI / DPP1 / Small Molecule / Respiratory / Immunology
    Non-Cystic Fibrosis Bronchiectasis (NCFB)MarketedActiveUSEUHidradenitis SuppurativaPhase 2ActiveGlobal
  • Amikacin Liposome Inhalation SuspensionARIKAYCE / Bacterial 30S ribosomal subunit / Liposomal Inhalation Suspension / Respiratory / Infectious Disease
    Refractory Mycobacterium avium complex (MAC) Lung DiseaseMarketedActiveUSEUJPMAC Lung Disease (Label Expansion)Phase 3ActiveGlobal
  • Treprostinil Palmitil Inhalation PowderTPIP / Prostacyclin receptor / Inhalation Powder / Respiratory / Pulmonary
    Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)Phase 3ActiveGlobalPulmonary Arterial Hypertension (PAH)Phase 3ActiveGlobalProgressive Pulmonary Fibrosis (PPF)Phase 3 PlannedActiveGlobal
  • INS1148INS1148 / Stem Cell Factor SCF248 / Monoclonal Antibody / Respiratory / Immunology
    Interstitial Lung Disease (ILD)Phase 2ActiveGlobalModerate-to-severe asthmaPhase 2ActiveGlobal
  • INS1033INS1033 / Unknown / Unknown / Immunology & Inflammation
    Inflammatory diseasesPreclinicalActiveGlobal
  • Intrathecal gene therapy for DMDDystrophin / Gene Therapy / Neurology / Rare Disease
    Duchenne Muscular Dystrophy (DMD)Phase 1ActiveGlobal
  • INS1202INS1202 / Unknown / Unknown / Neurology / Rare Disease
    Amyotrophic Lateral Sclerosis (ALS)Phase 1ActiveGlobal
  • Stargardt Disease Gene TherapyUnknown / Gene Therapy / Ophthalmology / Rare Disease
    Stargardt DiseasePreclinicalActiveGlobal
  • Next-Gen DPP1 InhibitorsDPP1 / Small Molecule / Immunology & Inflammation
    UndisclosedPreclinicalActiveGlobal

Jazz Pharmaceuticals PLC

jazzpharmaceuticals.com
9assets
  • ZanidatamabHER2 / Bispecific Antibody / Oncology
    Biliary Tract Cancers (BTC)Gastroesophageal Adenocarcinoma (GEA)Colorectal Cancer (CRC)
  • LurbinectedinZepzelca / DNA alkylating / Small Molecule / Oncology
    Small Cell Lung Cancer (SCLC)Ewing Sarcoma
  • DordaviproneModeyso / ClpP agonist / DRD2 antagonist / Small Molecule / Oncology
    H3 K27M-mutant diffuse glioma
  • Daunorubicin and cytarabineJZP351 / Vyxeos / Vyxeos Liposomal / Topoisomerase inhibitor / nucleoside metabolic inhibitor / Liposomal Combination / Oncology
    Myelodysplastic Syndromes (MDS)Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
  • JZP898JZP898 / IFNα2b cytokine pro-drug / Biologic / Oncology
    Solid Tumors
  • JZP3507JZP3507 / ClpP agonist / DRD2 antagonist / Small Molecule / Oncology
    Oncology
  • JZP815JZP815 / pan-RAF / Small Molecule / Oncology
    Solid TumorsHematologic Malignancies
  • CannabidiolEpidyolex / Cannabinoid Receptors / Small Molecule / Neuroscience
    Lennox-Gastaut Syndrome (LGS)Dravet Syndrome (DS)Tuberous Sclerosis Complex (TSC)
  • JZP441JZP441 / Orexin-2 receptor agonist / Small Molecule / Neuroscience
    Narcolepsy Type 1Idiopathic Hypersomnia

Merck & Company, Inc.

merck.com
9assets

Moderna, Inc.

modernatx.com
9assets

Sangamo Therapeutics, Inc.

sangamo.com
9assets
  • Isaralgagene civaparvovecST-920 / alpha-galactosidase A (GLA) / Gene Therapy (AAV) / Metabolic Diseases
    Fabry DiseaseBLA/FilingActiveUS
  • Giroctogene fitelparvovecSB-525 / Factor VIII / Gene Therapy (AAV) / Hematology
    Hemophilia APhase 3ActiveUS
  • ST-503ST-503 / Nav1.7 (SCN9A) / Gene Therapy (Zinc Finger Repressor, AAV9) / Neurology
    Small Fiber Neuropathy (Chronic Neuropathic Pain)Phase 1/2ActiveUS
  • ST-506ST-506 / Prion protein (PRNP) / Gene Therapy (Zinc Finger Repressor, STAC-BBB AAV) / Neurology
    Prion DiseasePreclinicalActiveUS
  • TX200TX200 / HLA-A2 / Cell Therapy (Autologous CAR-Treg) / Transplantation
    Prevention of Immune-Mediated Rejection in HLA-A2 Mismatched Kidney TransplantationPhase 1/2ActiveUSEurope
  • IL23R CAR-TregIL23R / Cell Therapy (CAR-Treg) / Autoimmunity
    Inflammatory Bowel Disease (Crohn's Disease)PreclinicalActiveGlobal
  • Genentech Tau ProgramTau / Gene Therapy (Zinc Finger Epigenetic Regulator) / Neurology
    Tauopathies / Alzheimer's DiseasePreclinicalActiveGlobal
  • Takeda Huntington's ProgramHTT / Gene Therapy (Zinc Finger Epigenetic Regulator) / Neurology
    Huntington's DiseasePreclinicalActiveGlobal
  • Alexion C9ORF72 ProgramC9ORF72 / Gene Therapy (Zinc Finger Transcription Factor) / Neurology
    Amyotrophic Lateral Sclerosis (ALS)PreclinicalActiveGlobalFrontotemporal Lobar Degeneration (FTLD)PreclinicalActiveGlobal

Teva Pharmaceutical Industries Limited

ir.tevapharm.com
9assets

Vertex Pharmaceuticals Incorporated

vrtx.com
9assets
  • SuzetrigineVX-548 / Journavx / NaV1.8 / Small Molecule / Pain
    Moderate-to-Severe Acute PainPainful Diabetic Peripheral Neuropathy
  • VX-993VX-993 / NaV1.8 / Small Molecule / Pain
    Painful Diabetic Peripheral NeuropathyModerate-to-Severe Acute Pain
  • Vanzacaftor/tezacaftor/deutivacaftorCFTR / Small Molecule / Cystic Fibrosis
    Cystic Fibrosis
  • VX-522VX-522 / CFTR / mRNA / Cystic Fibrosis
    Cystic Fibrosis (non-responsive to modulators)
  • InaxaplinVX-147 / APOL1 / Small Molecule / Kidney Disease
    APOL1-mediated Kidney Disease (AMKD)
  • VX-407VX-407 / PC1 / Small Molecule / Kidney Disease
    Autosomal Dominant Polycystic Kidney Disease (ADPKD)
  • VX-880VX-880 / Islet Cell / Cell Therapy / Type 1 Diabetes
    Type 1 Diabetes
  • VX-264VX-264 / Islet Cell / Cell Therapy / Type 1 Diabetes
    Type 1 Diabetes
  • PovetaciceptALPN-303 / BAFF/APRIL / Biologic / Autoimmune / Kidney Disease
    IgA Nephropathy

Xencor, Inc.

xencor.com
9assets
  • XmAb819XmAb819 / ENPP3 x CD3 / Bispecific Antibody / Oncology
    Clear Cell Renal Cell Carcinoma (ccRCC)Phase 1ActiveGlobalColorectal Cancer (CRC)Phase 1ActiveGlobalNon-Small Cell Lung Cancer (NSCLC)Phase 1ActiveGlobal
  • XmAb541XmAb541 / CLDN6 x CD3 / Bispecific Antibody / Oncology
    Ovarian CancerPhase 1ActiveGlobalGerm Cell Tumors (GCT)Phase 1ActiveGlobalSolid TumorsPhase 1ActiveGlobal
  • XmAb808XmAb808 / B7-H3 x CD28 / Bispecific Antibody / Oncology
    Prostate Cancer / Solid TumorsPhase 1ActiveGlobal
  • XmAb942XmAb942 / TL1A / Monoclonal Antibody / Immunology
    Ulcerative Colitis (UC)Phase 2ActiveGlobalInflammatory Bowel Disease (IBD)Phase 2ActiveGlobal
  • XmAb412XmAb412 / TL1A x IL23p19 / Bispecific Antibody / Immunology
    Inflammatory Bowel Disease (IBD)Phase 1ActiveGlobal
  • PlamotamabCD20 x CD3 / Bispecific Antibody / Immunology
    Rheumatoid ArthritisPhase 1ActiveGlobal
  • XmAb657XmAb657 / CD19 x CD3 / Bispecific Antibody / Immunology
    Idiopathic Inflammatory MyositisPhase 1ActiveGlobal
  • ObexelimabCD19 x FcγRIIb / Monoclonal Antibody / Immunology
    Autoimmune DiseasesPhase 3ActiveGlobal
  • TobevibartHepatitis B Virus / Monoclonal Antibody / Infectious Disease
    Chronic Hepatitis B / Hepatitis DPhase 3ActiveGlobal